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1. Summary
Metabolic energy is most eﬃciently stored as triacylglycerol (TAG). This neutral lipid ac-
cumulates mainly within adipose tissues, but it can be stored and used in all types of cells.
Within cells it is packed in organelles called lipid droplets (LDs). They consist of a core
of neutral lipids like TAG and cholesterol esters, which is surrounded by a phospholipid
monolayer that mainly consists of phosphatidylcholine (PC). Attached to or inserted into
this monolayer are various proteins, mainly LD speciﬁc structural proteins or lipid metabolic
enzymes. Though excess uptake of nutrition leads to lipid accumulation in all kinds of body
tissues, which is accompanied by the augmentation of LDs and results in cellular dysfunction
and the development of metabolic diseases, relatively little is known about the biogenesis
and growth of LDs.
This thesis focuses on diacylglycerol acyltransferase 2 (DGAT2), an enzyme of the TAG
biosynthetic pathway, and on lyso-phosphatidylcholine acyltransferases 1 and 2 (LPCAT1
and LPCAT2), both enzymes of one of the PC biosynthetic pathways called Lands cycle.
The data presented in this thesis show that these enzymes can localize to LDs and that they
actively synthesize TAG and PC at the surface of LDs. While the LPCATs reside on LDs
independent from the nutrition status of the cell, DGAT2 accumulates on LDs upon excess
availability of oleic acid.
DGAT2, LPCAT1 and LPCAT2 diﬀer in their structure from other iso-enzymes that catalyze
the same reactions. This thesis shows that they exhibit a monotopic conformation and that
they contain a hydrophobic stretch that presumably forms a hairpin. This topology enables
them to localize to both a phospholipid bilayer like the membrane of the endoplasmic retic-
ulum and to a phospholipid monolayer like the surface of LDs. The diﬀerent biophysical
properties of the structures of iso-enzymes might be responsible for their subcellular localiza-
tion and the formation of distinct TAG or PC pools that are destined for diﬀerent purposes.
This would explain, why the iso-enzymes are often not able to replace each other.
Knock-down and overexpression experiments performed in this thesis show that the activity
of LPCAT1, LPCAT2 and DGAT2 inﬂuence the packaging of lipids within LDs. Knock-down
1
1. Summary
of LPCAT1 and LPCAT2 leads to an increase in LD size without concomitant increase in
the amount of TAG. Combined with the ﬁnding that the proﬁle of the PC species of the LD
surface reﬂects the substrate preferences of LPCAT1 and LPCAT2, the results suggest that
these enzymes are responsible for the formation of the LD surface. Therefore, the increase in
LD size upon LPCAT1 and LPCAT2 knock-down results from an adjustment of the surface-
to-volume ratio in response to reduced availability of surface lipids. The connection between
LPCATs and LD size was corroborated in the model organism Drosophila melanogaster.
Three diﬀerent knockout ﬂy strains of the Drosophila homologue of LPCAT1 and LPCAT2,
CG32699, exhibit enlarged LDs in the fat body of the L3 larvae. Furthermore, the data
presented suggest that the morphology of LDs is important for the secretion of stored lipids.
The reduction of LPCAT1 in liver cells leads to a reduction in lipoprotein particle release.
This was shown by measuring the amount of released apolipoproteinB with two diﬀerent
methods, by measuring the release of lipids and by quantiﬁcation of the amount of released
hepatitis C virus, which is known to rely on LD interaction for replication and on lipoprotein
particles for cellular release.
DGAT2 is recruited to LDs upon excess availability of oleic acid and its overexpression leads
to the formation of many, but relatively small LDs. Here, it is shown that DGAT2 interacts
with acyl-CoA synthetase ligase 1 (ACSL1), an enzyme that catalyzes the activation of free
fatty acids with Coenzyme A. This interaction does not inﬂuence the stability of DGAT2
nor does it seem to aﬀect lipid synthesis. Nevertheless, it shows an inﬂuence on lipid
packaging in LDs. While overexpression of DGAT2 results in the appearance of smaller
LDs, overexpression of ACSL1 leads to an increase in LD size. Coexpression of ACSL1 and
DGAT2 reverses the phenotypes obtained by single overexpression and normalizes the mean
LD diameter to values observed at normal conditions.
In conclusion, this thesis shows that LDs are able to synthesize the components of their core
and their surface, which underlines their independent function in metabolism. Additionally,
the results show that LDs can grow by local synthesis and that the responsible enzymes
exhibit a monotopic membrane topology, which might be crucial for LD localization. Fur-
thermore, the obtained data suggest that the localization and the ratio between diﬀerent
enzyme activities inﬂuence the packaging of lipids and aﬀects lipid secretion and therefore
impact the whole body lipid metabolism.
2
2. Introduction
This chapter gives an overview about the role of lipids and their metabolism in cells. It
describes how major lipids are synthesized, stored and mobilized, and what the consequences
are, if these processes are disturbed. Additionally, more detailed information is provided
about lipid metabolic enzymes, which are subject of further investigation within this thesis.
2.1. Lipids and life
Lipids are important components of cells. They separate the cell from its surroundings by
formation of a cell membrane. Additionally, they create diﬀerent compartments within the
cell by the formation of organelle membranes. Besides their structural role, they participate
in protein modiﬁcation, signaling and hormonal regulation and they provide energy for
cellular processes. There are diverse lipids, which diﬀer in their physical and chemical
properties and participate in many processes within organisms. While phospholipids are
amphipathic molecules that are optimized for the separation of lipid and water phases,
neutral lipids like triacylgylcerides (TAG) are optimized as energy containing molecules.
The characteristics of TAG allow a dense packing of these molecules [1]. They accumulate
in lipid droplets (LDs). Most neutral lipids in the body are stored in adipose tissues,
which are specialized to store TAG and to release them upon energy requisition. Besides
their function in lipid storage, adipose tissues participate in hormonal regulation and organ
protection.
2.2. Lipid droplets (LDs)
LDs are the cellular location of neutral lipid storage. Every eukaryotic cell analyzed so far
is able to form LDs [2]. Some cells exhibit LDs under normal physiological conditions, while
others must be induced to LD formation by the addition of lipids. LDs have a uniform
ultrastructure, but they diﬀer in size between diﬀerent cell types. Adipocytes exhibit few
3
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large droplets [3, 4], whereas muscle cells have multiple small droplets [5, 6]. Some cells
have many droplets of equal size, others have droplets of a broad range of size. In some cell
types LDs aggregate in big clusters, often close to the nucleus, whereas in others they are
very dispersed and located to the cell periphery.
2.2.1. Structure of LDs
LDs consist of a core of neutral lipids like TAG and cholesterol esters (CE), which is sur-
rounded by a monolayer of phospholipids (ﬁgure 2.1). This monolayer is characteristic for
LDs and consists mainly of phosphatidylcholine (PC) [7, 8]. Several proteomic analyses of
puriﬁed LDs from diﬀerent cell types revealed that diﬀerent proteins are attached to LDs,
which can be classiﬁed into structural components, lipid metabolic enzymes and proteins
belonging to other processes like ubiquitination, signaling and membrane traﬃc [9–16].
The most abundant structural proteins of LDs belong to the PAT-family, named after its
members perilipin, adipophilin (ADRP) and tail-interacting protein 47 (TIP47), which share
a characteristic PAT1 homology region. Perilipin [17] is highly expressed in adipose tissue,
while ADRP [18, 19] and TIP47 [20–22] are found on LDs of many cell types. The additional
family members OXPAT/MLDP [23] and S3-12 [24] are found mainly in oxidative tissues
and white adipose tissue, respectively. In adipocytes, smaller LDs harbor mainly TIP47
and S3-12, whereas ADRP and perilipin are found predominantly on large droplets. During
adipocyte diﬀerentiation, the PAT family members S3-12 and TIP47 are replaced by ADRP
and perilipin [25]. Besides their structural function, PAT family proteins seem to be involved
in LD biogenesis and regulation of lipolysis (see section 2.2.3 and 2.2.4). Additionally, LDs
harbor many proteins involved in lipid metabolism, for example acyl-CoA synthetase ligase
(ACSL) family member 1, 3 and 4, NAD(P)H steroid dehydrogenase-like protein (NSDHL)
or lipases such as hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL).
The set of proteins localizing to LDs depends on the cell type and can change upon hormonal
or nutritional stimulation.
Similarly, the lipid components of LDs vary between cell types. Besides TAG, the core
of LDs harbors diacylglycerol (DAG), CE and other esters like retinol esters in diﬀerent
proportions [26–28]. The phospholipid monolayer consists mainly of PC, but contains also
phosphatidylethanolamine (PE), phosphatidylinositol (PI), lyso-phosphatidylcholine (LPC),
lyso-phosphatidylethanolamine (LPE) and free cholesterol [8, 29].
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Figure 2.1.: Structure of lipid droplets
2.2.2. Function of LDs
Besides their role in storage of energetic molecules and precursors for membranes, steroid
hormones and signaling molecules, LDs are suggested to function in detoxiﬁcation. Some
cellular lipids, for example LPC or free fatty acids (FFAs), are toxic for the cell, if they ac-
cumulate, and LDs might serve to sequester them [30]. It has been suggested that they have
a similar function for proteins. LDs can sequester proteins for future use or for degradation
[31], for example histones accumulate on LDs in Drosophila embryos [32]. The localization
of many proteins involved in ubiquitination to LDs further suggests a role in protein degra-
dation. Additionally, LDs seem to play a role in infection and inﬂammation. It was reported
that LDs are formed in leukocytes following bacterial infection [33, 34]. The increase of LD
number correlated with an increased generation of eicosanoids. Furthermore, LDs function
in hepatitis C virus assembly [35–37] and replication of Chlamydia trachomatis [38].
2.2.3. Biogenesis of LDs
Though LDs were studied intensively for several years, their origin is still unclear. Whether
they originate from other organelles or represent self-replicating organelles is a matter of
debate. Most theories suggest the ER as site for LD formation (ﬁgure 2.2). Electron
microscopic images show LDs in close contact to ER membranes and ADRP-rich egg-cup
like domains that might represent the location for LD assembly [39]. In the monolayer
budding theory, neutral lipids accumulate between the leaﬂets of the ER membrane. This
lipid accumulation bulges out into the cytosol and is ﬁnally released by budding. Thus
the phospholipid monolayer would be derived from the cytoplasmic leaﬂet of the ER. In
the bicelle formation or hatching theory, the lipid accumulation between the ER leaﬂets is
released by disruption of the membrane next to the accumulation. Thus the phospholipid
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Figure 2.2.: Models of lipid-droplet biogenesis
Model 1: LD biogenesis by ER budding. Neutral lipids (orange) are synthesized by neutral lipid-synthesizing
enzymes (NLSE) and bulge from the outer leaﬂet of the ER membrane (red). The nascent droplet may be coated
by proteins (dark blue) that facilitate the budding process. Model 2: Bilayer excision. Newly synthesized neutral
lipids accumulate between the inner (blue) and outer (red) leaﬂets of the ER membrane and cause bulging. This
entire lipid lens is then excised from the ER, leaving a transient hole in the membrane. ER contents (yellow) might
leak through this hole into the cytosol. Model 3: Vesicular budding. A vesicle containing both leaﬂets of the ER
membrane (red and blue) and a lumen (yellow) is formed by the vesicular budding machinery (green) at the ER
membrane. The vesicle is subsequently tethered to the ER, where NLSEs (grey) ﬁll the intramembranous space with
neutral lipids (orange). The luminal space (yellow) is compressed, and its contents may leak into the cytosol. This
process may trap luminal proteins within a compartment of the LD. This ﬁgure is taken from [40].
monolayer of the LD would be derived from both leaﬂets of the ER membrane. The opening
of the ER compartment generated during LD release has been suggested to participate
in ER-associated degradation of proteins and the release of viruses from the ER lumen.
In the vesicular budding theory, vesicles are formed and stay tethered to the ER. The
intramembrane space of these vesicles is then ﬁlled with neutral lipids, which displace the
vesicular lumen until it remains as an aqueous inclusion within the LD or is released into
the cytosol ([40] and references therein).
2.2.4. Mobilization of stored lipids
The best-studied process concerning LDs is the release of stored TAG. Besides a cellu-
lar basal level, lipolysis is stimulated by multiple signaling pathways. In the classical
hormonal pathway, catecholamines activate the 훽-adrenergic receptor. This leads to the
activation of protein kinase A via the G-protein coupled activation of adenylate cyclase and
increased levels of cAMP [41]. Protein kinase A phosphorylates perilipin A and hormone-
sensitive lipase (HSL) [42, 43] (ﬁgure 2.3). The phosphorylation leads to the release of
comparative gene identiﬁcation-58 (CGI-58) from the LD [44]. CGI-58 can interact with
adipose triacylglyceride lipase (ATGL) and seems to activate the enzyme [45]. ATGL is
reported to hydrolyse TAG into DAG and fatty acid (FA) [46]. DAG is hydrolyzed by HSL
to monoacylglycerol (MAG) and FA [42]. During hormonal stimulation of lipolysis, HSL
translocates from the cytosol to LDs and binds to phosphorylated perilipin A [47, 48]. The
last step in TAG lipolysis is catalyzed by monoacylglycerol lipase (MGL), which hydrolyses
MAG to glycerol and FA [49].
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Figure 2.3.: Lipolysis
Perilipin regulates both ATGL and HSL activity by binding the ATGL activator CGI-58 and by controlling the
access of HSL to the LD. In the basal state, CGI-58 is bound to perilipin and HSL is predominantly cytosolic
resulting in low LD-associated ATGL and HSL activity. ATGL is present on LDs at similar amounts in non-
stimulated and stimulated adipocytes excluding an activation mechanism based on translocation. In the activated
state, phosphorylation of perilipin by PKA leads to the release of CGI-58, which then becomes available for ATGL
activation. Activated ATGL generates diacylglycerol (DG), the preferred substrate of HSL. In parallel, HSL is
phosphorylated by PKA and perilipin promotes the translocation of the enzyme resulting in eﬃcient DG hydrolysis.
The last step in triacylglycerol (TG) degradation is performed by cytosolic MGL ﬁnally resulting in the formation
of free glycerol and FA. This ﬁgure is take from [50].
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The PAT family proteins on the surface of LDs are thought to represent key controllers
in lipolysis, as they seem to shield TAG from lipolysis [51–53] and the phosphorylation
of perilipin A is required to activate HSL and ATGL [54]. Additionally, they seem to
be important for the dramatic morphological changes that LDs undergo during lipolysis.
Chronic stimulation of lipolysis in adipocytes results in a fragmentation of large LDs into
small LDs, which are dispersed throughout the cell [3, 9]. A similar fragmentation connected
with increased lipolysis could be achieved by ablation of the fat speciﬁc protein 27 (Fsp27) in
adipocytes. Fsp27 is reported to be involved in the formation of large LDs [55, 56]. Though
many players in lipolysis are known, the regulation of lipolysis is not completely understood,
especially as most data result from studies in adipocytes only.
2.2.5. Storage of lipids
Though the main lipid composition of LDs is known, and the synthesis pathways of most
stored lipids have been investigated, relatively little is known about how lipids are stored
within the LDs. Most enzymes for complex lipid synthesis localize to the ER, but how the
synthesized lipids enter the LD is still a matter of debate (see section 2.5). The main storage
lipid TAG derives from glycerol and FAs in several enzymatically catalyzed synthesis steps,
which are described further in section 2.3.
The FAs for the synthesis of storage lipids can derive from diﬀerent sources. FAs can be
imported into the cell, they can be synthesized de novo within the cell or they derive from
stored lipids via lipolysis (see section 2.2.4). FAs are generally synthesized in the cytosol
by the multifunctional polypeptide proteins acetyl-CoA carboxylase (ACC) and fatty acid
synthase (FAS) from acetyl-CoA and malonyl-CoA. De novo synthesis mainly takes place
in mammary gland for milk production, and in liver and adipose tissue for the synthesis of
TAG. It is tightly regulated by the nutritional status and hormones [57].
The cellular import of FAs has been studied intensively, but the exact mechanism still
remains to be elucidated. One possibility is the transport of FAs via membranes by ﬂip-
ﬂop [58, 59], the other possibility requires several FA transport and binding proteins. In
particular, the FA translocase (FAT/CD36) was reported to play a major role in protein-
facilitated FA uptake [60–62]. The driving force for FA uptake seems to be the sequestration
of FFA within the cell [63, 64]. As large amounts of FFAs are cytotoxic, they are immediately
bound to soluble intracellular transport proteins like fatty acid binding proteins (FABPs)
[65–67] and fatty acid transport proteins (FATPs) [68] or after activation with CoA they
are bound to acyl-CoA binding proteins (ACBPs) [69]. After their activation by acyl-CoA
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synthethases ligases (ACSLs) FAs are degraded by 훽-oxidation or incorporated into complex
lipids like phospholipids or TAG.
2.2.5.1. Acyl-CoA synthetases ligases (ACSLs)
The addition of FAs to a glycerol or cholesterol backbone requires energy. Therefore, FAs
have to be activated with CoA in order to be used by enzymes for the synthesis of lipids. This
activation is catalyzed by acyl-CoA-acyltransferases (ACSLs). The activation is a two-step
reaction: ﬁrst, ATP and magnesium are used to activate a FA to AMP-acyl accompanied
by the release of pyrophosphate (PP), second, AMP-acyl is linked to Coenzyme A via its
sulﬁde (SH) group following the release of AMP. This process results in acyl-Coenzyme A
[70] that can be used in diverse lipid metabolic pathways.
In humans, at least ﬁve ACSL isoforms (ACSL1, ACSL3, ACSL4, ACSL5 and ACSL6) with
diﬀerent tissue distributions and subcellular localizations have been detected [71–73]. They
are divided into two subgroups, one of which comprises ACSL1, 5 and 6, the other ACSL3
and 4 [74]. While ACSL3 was reported to be involved in LD formation, PC synthesis,
lipoprotein secretion and control of lipogenic gene expression [75–78], ACSL4 seems to be
involved in hepatocellular carcinoma growth [79, 80] and may be linked to TAG synthesis
[71].
ACSL1 is very abundant in adipocytes and liver. It is reported to localize to the ER,
mitochondria-associated membranes (MAM) [81] and cytosol [71] in hepatocytes and to the
plasma membrane (PM) and mitochondria in 3T3-L1 adipocytes [82, 83]. ACSL1 expression
is reported to be regulated by the transcription factors PPAR훼 and PPAR훾 depending on
cell type and study conditions [84]. These ﬁndings and studies from liver-speciﬁc knock-
out mice implicate a function in lipogenesis as well as in 훽-oxidation [85]. In hepatocytes,
ACSL1 promotes FA incorporation into TAG [86], channels FAs away from CE into DAG
and phospholipid synthesis and increases FA reacylation [81]. In adipocytes, ACSL1 in-
teracts with FATP1, a FA transporter at the PM. There, ACSL1 activity is necessary for
the activity of FATP1 by directly activating and mitigating incoming FAs. This process of
channeling is called vectorial acylation [83, 87]. In contrast, knock-down studies on ACSL1
in adipocytes did not conﬁrm a role in FA uptake, but indicate a role in FA reesteriﬁcation
following lipolysis [88].
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2.3. TAG biosynthesis
TAG synthesis combines the products of glycolysis, in particular glycerol-3-phosphate, with
acyl-CoA. In a four-step reaction, glycerol is dephosphorylated and three FAs are esteri-
ﬁed to the glycerol backbone (ﬁgure 2.4 and reviewed in Coleman et al. [89]). The ﬁrst
step, the formation of lyso-phosphatidate (LPA) or 1-acylglycerolphosphate, is catalyzed by
glycerolphosphate acyltransferase (GPAT), which represents the rate-limiting step of TAG
synthesis. The second step, the addition of another FA to yield phosphatidic acid or 1,2-
diacylglycerolphosphate, is catalyzed by acylglycerolphosphate acyltransferase (AGPAT/
LPAAT). In the third step, the phosphate is removed from 1,2-diacylglycerolphosphate by
the action of phosphatidic acid phosphatase (PAP, lipin). In the last step, the resulting
diacylglycerol is converted to TAG by the addition of another FA at the sn-3 position. This
reaction is catalyzed by the diacylglycerol acyltransferases (see section 2.3.1), which deter-
mine whether DAG is used for TAG synthesis or whether it participates in phospholipid
synthesis (see section 2.4).
2.3.1. Diacylglycerol acyltransferases (DGATs)
TAGs are mainly synthesized by the glycerol-3-phosphate pathway. The last step in the
formation of TAG, the addition of an activated FA to diacylglycerol, is catalyzed by diacyl-
glycerol acyltransferases (DGATs). In mammals, two isoforms are known, DGAT1 and
DGAT2, which share no sequence homology and belong to diﬀerent protein families. Both
isoforms are ubiquitously expressed with highest expression in white adipose tissue, small
intestine, liver and mammary gland [90]. Both proteins are membrane proteins. While
DGAT1 has multiple transmembrane domains [91], DGAT2 possesses only one hydrophobic
stretch and a monotopic topology (see section 4.3.2 and [92]).
In mice, DGAT1 knock-out led to reduced TAG levels, resistance to diet-induced obesity
and increased sensitivity to leptin and insulin [93, 94] suggesting a role in the regulation of
energy metabolism. Knock-out of DGAT2 led to lipopenic mice with impaired skin barrier
permeability that died soon after birth, demonstrating that DGAT2 is essential for survival
[95]. While DGAT2 mainly catalyzes the formation of TAG, DGAT1 accepts also other
substrates like retinol, waxes and MAG, especially in the intestine [96, 97].
Expression of DGAT2 in adipocytes is regulated by the transcription factor C/EBP [98] and
by leptin [99]. Leptin reduces DGAT2 expression, but has no inﬂuence on DGAT1. Similarly,
suppression of DGAT2 in rats leads to a reduced expression of lipogenic genes, but increases
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Figure 2.4.: Pathway of triacylglycerol and phosphatidylcholine synthesis
Synthesis of TAG is shown on the left side, synthesis of PC on the right side. Enzymes are labeled in green,
phosphate in red, cytosine in yellow, choline in light blue, fatty acids in dark blue and glycerol in black. G3P,
glycerol-3-phosphate; LPA, lyso-phosphatidic acid; PA, phosphatidic acid; DAG, diacylglycerol; TAG, triacylglycerol;
choline-P, cholinephosphate; PC, phosphatidylcholine; LPC, lyso-phosphatidylcholine; GPAT, glycerolphosphate
acyltransferase; AGPAT, acylglycerolphosphate acyltransferase; PAP, phosphatidic acid phosphatase; DGAT, di-
acylglycerol acyltransferases; CK, choline kinase; CT, CTP-phosphocholine cytidylyltransferase; CPT, CDP-choline
1,2-diacylglycerol cholinephosphotransferase; PLA2, phospholipase A2; LPCAT, lyso-phosphatidylcholine acyltrans-
ferase.
expression of oxidative genes in the liver that reverses diet-induced hepatic steatosis and
insulin resistance, whereas suppression of DGAT1 shows no similar eﬀect [100].
DGAT1 and DGAT2 localize to the ER compartment and upon addition of oleate DGAT2
localizes to LDs (see section 4.1.1.1 and [28, 101]). Recently, a sequence was identiﬁed in
DGAT2 that seems to be responsible to recruit DGAT2 to MAM within the ER compart-
ment [101]. Furthermore, DGAT2 was reported to colocalize with the ER protein stearoyl-
CoenzymeA desaturase (SCD) in Hela cells, which is also present in MAM and is important
for the accumulation of TAG [102, 103].
2.4. PC biosynthesis
PC is synthesized by two diﬀerent pathways (ﬁgure 2.4). One pathway is called the de
novo or Kennedy pathway [104]. In this three-step reaction, choline is activated and trans-
ferred to DAG. First, choline is activated by phosphorylation to cholinephosphate by the
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choline kinase (CK) and subsequent reaction with CTP, catalyzed by CTP-phosphocholine
cytidylyltransferase (CT), which yields CDP-choline and PP. In the last step, CDP-choline
1,2-diacylglycerol cholinephosphotransferase (CPT) catalyzes the transfer of cholinephos-
phate to DAG accompanied by the release of CMP, which results in the formation of PC.
The other pathway is called the membrane-remodeling pathway or Lands cycle [105]. The
Lands cycle is crucial for the insertion of arachidonate into glycerophospholipids and the
formation of platelet activating factor (PAF), both of which are important in inﬂammatory
processes. Here, PC derives from LPC by the addition of acyl-CoA. LPC mainly originates
from PC by the release of the FA at its sn-2 position. This reaction is catalyzed by phos-
pholipase A2. The reverse process, the formation of PC from LPC, is catalyzed by enzymes
called lyso-phosphatidylcholine acyltransferases (LPCATs).
2.4.1. Lyso-phosphatidylcholine acyltransferases (LPCATs)
Recently, four LPCATs were cloned and characterized [106–111]. LPCAT1 and LPCAT2
belong to the lyso-phosphatidic acid acyltransferase (LPAAT) family, characterized by the
presence of four conserved motifs [112], and possess a C-terminal ER retention motif. In
contrast, LPCAT3 and LPCAT4 lack LPAAT motifs and are related to proteins of the
membrane-bound O-acyltransferase (MBOAT) family [113], which includes the cholesterol
acyltransferase ACAT1 and DGAT1. LPCAT1 is highly expressed in lung tissue, especially
in type II alveolar cells [107], and it was also detected in red blood cells [109]. LPCAT2
expression is highest in resident macrophages and casein-induced neutrophils [108]. Both
isoforms contain Ca2+-binding EF-hand motifs and LPCAT2 activity is Ca2+-dependent,
whereas contradictory results were obtained for LPCAT1 activity [106, 107, 109, 114].
LPCAT1 is supposed to be important for the production of lung surfactant [106, 107,
115], a function that is reﬂected by its substrate speciﬁcity. It prefers medium-chain (C6-
C14) saturated and long-chain (C18) unsaturated acyl-CoAs and catalyzes the formation
of dipalmitoyl-PC [106, 107, 111, 116]. Increasing concentration of substrates shifts the
preference towards unsaturated short-/medium-chain acyl-CoAs [114]. Recently, lyso-PAF
acyltransferase activity of LPCAT1 was demonstrated [114]. The activity and expression of
LPCAT1 is independent of any inﬂammatory stimulation, in contrast to LPCAT2. Upon
acute inﬂammation LPCAT2 transfers acetyl-CoA to lyso-PAF to form PAF. Under resting
conditions it participates in membrane-remodeling through insertion of arachidonyl-CoA
into PC [108, 116]. Beside acetyl-CoA and arachidonyl-CoA, LPCAT2 exhibits a similarly
broad substrate preference as LPCAT1 [111].
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LPCAT3 is highly expressed in lung, thymus and adipocytes [117]. Additionally, it is the
main LPCAT in liver cells [110]. As substrates it prefers long-chain unsaturated acyl-CoAs
in vitro [110, 111, 117], but it seems to incorporate preferably saturated medium-chain FA in
vivo, as was shown by overexpression in Sf9 insect cells or knockdown in HEK293 cells [118].
LPCAT4 is highly expressed in epididymis, brain, testis and ovary and utilizes preferentially
oleoyl-CoA [111, 116].
2.5. Dynamics of lipids
Lipids are in a constant ﬂux and are continuously converted into each other. Within cells,
FAs are transported by FABPs and FATPs (see section 2.2.5). Also transport proteins for
more complex lipids were reported for example the StAR-related lipid transfer (START) do-
main proteins [119]. Alternatively, lipids can be distributed by diﬀusion within membranes
or between organelles via membrane continuities. Those continuities were reported between
LDs and ER [13, 120, 121]. Additionally, LDs seem to stay in contact with other organelles
like endosomes [122], peroxisomes [123], lysosomes, autophagosomes [124, 125] and mito-
chondria [126, 127] (ﬁgure 2.5). Furthermore, lipids can be exchanged between organelles
by vesicular transport. LDs themselves are mobile. They can be transported along micro-
tubules within cells [128, 129]. Additionally, LDs are able to fuse with each other [130, 131].
Also the TAG stored within LDs underlies a permanent turnover in cycles of lipolysis and
reesteriﬁcation.
Extracellularly, lipids are transported in lipoproteins. These lipoproteins are soluble com-
plexes of proteins (apolipoproteins) and lipids that are transported in the circulation of
vertebrates and insects and that are synthesized in the liver and intestine. They are classi-
ﬁed into chylomicrons (CM), very low density (VLDL), low density (LDL) and high density
(HDL) lipoproteins based on their apolipoprotein component and their density, which is
determined by the lipid composition [57]. Like LDs, they contain a core of neutral lipids
(TAG, CE) surrounded by phospholipids and cholesterol. TAG is secreted from the liver and
intestine in apolipoproteinB (apoB) containing lipoproteins (CM and VLDL). In contrast
to other apolipoproteins, apoB is not exchangeable between lipoproteins and resides in the
plasma in a lipid-associated form only. While VLDL and CM contain apoE, apoC and apoB,
LDL harbors exclusively apoB. ApoB is synthesized in the liver and is loaded with lipids in
the ER and Golgi. Especially the neutral lipids are transferred to apoB by the luminal ER
protein microsomal triacylglycerol transfer protein (MTP) [133]. In the absence of loaded
lipids apoB cannot be secreted and is rapidly degraded [134, 135]. The TAG secreted as CM
and VLDL mainly derives from TAG stored in cytosolic LDs [136].
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Figure 2.5.: Overview of the dynamics of LDs and their connection to diﬀerent cellular processes
This ﬁgure is taken from [132]. For abbreviations of glycerolipid synthesis see section 2.3, for FA synthesis and
transport proteins see section 2.2.5, for lipolysis see section 2.2.4 and for lipoprotein metabolism see section 2.5.
CPT1, carnitine/acylcarnitine translocase 1; NHR, nuclear hormone receptor; TNF훼, tumor necrosis factor 훼
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Figure 2.6.: Simpliﬁed receptor-mediated human lipoprotein metabolism
The liver is the crossing point between the exogenous pathway, which deals with dietary lipids, and the endogenous
pathway that starts with the hepatic synthesis of very low density lipoprotein particles (VLDL). The endogenous
metabolic branch starts with the production of chylomicrons (CM) in the intestine, which are converted to chy-
lomicron remnants (CMR). VLDL are lipolyzed to low density lipoprotein particles (LDL), which bind to the LDL
receptor. IDL, intermediate density lipoproteins; HDL, high density lipoproteins; LCAT, lecithin:cholesterol acyl-
transferase; CETP, cholesterol ester transferprotein; arrowhead, LDL receptor-related protein; arrowback, LDL-
receptor. ’Lipolysis’ denotes lipoprotein lipase-catalyzed TAG lipolysis in the capillary bed. This ﬁgure is taken
from [57].
VLDLs and CMs are converted into intermediate density lipoproteins (IDL) and LDL by
lipase activities within the circulation (ﬁgure 2.6). The major plasma TAG lipase is the
lipoprotein lipase (LPL). While LPL is secreted mainly by adipose and muscle tissues,
hepatic lipase is located to the liver. It converts VLDL remnants (IDLs) into LDLs by
lipolysis of TAG. FAs released from lipoproteins are bound to serum albumin and taken up
by cells (see section 2.2.5). Most lipoproteins are cleared from the circulation by lipoprotein
receptors (VLDL-, LDL- and scavenger receptor).
2.6. Lipids and diseases
Storage and release of lipids, their consumption and uptake are regulated by several factors
and signaling pathways. Already the deﬁciency of a single factor can cause an imbalance that
results in the development of diseases. Mutations in CGI-58 cause the Chanarin-Dorfman
Syndrome characterized by the accumulation of TAG in multiple tissues [45, 137]. A similar
phenotype appears upon mutations in ATGL, which causes the so-called neutral lipid storage
disease with myopathy [138]. In the Niemann-Pick disease type C, the Niemann-Pick C
genes are disrupted. This leads to a defect in endosomal cholesterol transport following
the accumulation of unesteriﬁed cholesterol in late endocytic organelles, which results in
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neurodegeneration [139]. In contrast, the disruption of Berardinelli-Seip congenital lipo-
dystrophy 2 (BSCL2, seipin) [140] and caveolin-1 [141] results in a complete or partial lack
of adipose tissue.
Many metabolic disorders derive from additive defects in diﬀerent pathways that can grad-
ually progress into more severe diseases. The ﬁrst step is usually the excess storage of lipids
within diﬀerent body tissues resulting in the development of obesity [142, 143]. Obesity
is correlated to a set of metabolic disorders summarized as metabolic syndrome. This in-
cludes insulin resistance and type-2 diabetes [144, 145], hepatic steatosis [146], inﬂammation,
atherosclerosis [147] and other cardiovascular diseases. Furthermore, it correlates with the
development of neurological diseases like Alzheimer disease [148, 149].
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3. Aim of the thesis
Lipids are stored within cells in organelles called lipid droplets (LDs). They consist of a
hydrophobic core of neutral lipids like triacylglycerol (TAG), surrounded by a monolayer
of phospholipids mainly containing phosphatidylcholine (PC). Excess storage of lipids is
associated with cellular dysfunctions and the development of diseases. Treatment of these
diseases requires detailed knowledge of the proper function of the processes and the key play-
ers involved. Though detailed but incomplete information on hydrolysis of storage lipids and
lipoprotein metabolism was achieved, relatively little is known about the biogenesis and the
liposynthetic metabolism of LDs. Most enzymes involved in lipid synthesis and degradation
are identiﬁed, but their precise role in the synthesis and incorporation of complex lipids into
LDs and subsequent LD growth still needs to be elucidated.
The aim of this thesis is to gain knowledge of the connection between lipid synthesis and
growth of LDs. In particular, the following key questions will be addressed:
 Are LDs able to grow by local synthesis of their main components TAG and PC?
 What enzymes are responsible for this LD-localized synthesis?
 What is the localization and the topology of these enzymes?
 What is the physiological role of this LD-localized synthesis?
 Are other proteins like speciﬁc interaction partners involved in regulation of these
enzymes?
In conclusion, this thesis will provide detailed new information on lipid metabolic processes
closely linked to LDs.
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4. Results
This chapter deals with the lipid droplet localized synthesis of triacylglycerol (TAG) and
phosphatidylcholine (PC), which are the main components of lipid droplets (LDs). The
ﬁrst part focuses on the identiﬁcation, localization and activity of enzymes that are respon-
sible for the synthesis of these lipids. The second part goes further into detail about the
importance of the LD surface, consisting mainly of PC, in the context of LD morphology
and cell physiology. In the third part the membrane topology of the enzymes, responsible
for the synthesis of these lipids, is investigated, especially with regard to the phospholipid
monolayer surrounding LDs. The last part concentrates on the regulation of TAG synthesis
by interactions between the responsible enzyme DGAT2 and other proteins.
4.1. LDs locally synthesize their lipid components
This ﬁrst section presents the ﬁrst evidence that LDs are able to locally synthesize the lipids
of their core (TAG) and their surface (PC), which endows the LDs a more independent
status than assumed before.
4.1.1. DGAT2 catalyzes the formation of TAG on LDs
TAGs are mainly synthesized by the glycerol-3-phosphate pathway (section 2.3). The last
step in the formation of TAG, the addition of an activated fatty acid to diacylglycerol, is
catalyzed by diacylglycerol acyltransferases (DGATs) [89]. The generation of knockout mice
of the two DGAT iso-enzymes revealed that DGAT1 is important to maintain the skin and
a normal energy metabolism, while DGAT2 is essential for survival [95]. In order to under-
stand the basic regulation of lipid metabolism in the context of LDs, this thesis is therefore
focused on the function of DGAT2.
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4.1.1.1. Localization of DGAT2 in COS7 cells
Untreated COS7 cells contain an insuﬃcient amount of DGAT2 for detection with our
DGAT2 antibody. Additionally, tags at the termini of the DGAT2 protein interfere with
a physiological localization of DGAT2 [28]. Therefore wildtype human DGAT2 was over-
expressed in COS7 cells and its localization was analyzed under diﬀerent nutritional condi-
tions. Detection of DGAT2 results in the staining of a reticular structure representing the
ER compartment, but upon the addition of oleate DGAT2 staining accumulates in ring-like
structures surrounding LDs (ﬁgure 4.1). This localization to LDs is supported by data from
another study [101]. Furthermore, endogenous DGAT2 can be found at the vicinity of LDs
in mouse adipocytes [28].
Figure 4.1.: Cellular localization of DGAT2
COS7 cells were transfected with wildtype human DGAT2 for 24 h. Cells were grown in DMEM medium supple-
mented with delipidated FCS (DL), normal FCS (FCS) or FCS and 100 휇M oleate (oleate). Cells were analyzed
by immunoﬂuorescence for LDs (green) and DGAT2 (red). See supplementary ﬁgure A.1 for the image (oleate)
separated into single channels. Scalebar = 10 휇m
In order to distinguish, whether DGAT2 localizes to the ER compartment at the vicinity of
LDs or directly to their surface, LDs were isolated from oleate-fed, DGAT2-overexpressing
COS7 cells in a sucrose density gradient (see section 6.2.2.7). The western blot analysis of
the abundance of DGAT2 and the ER membrane protein ACAT1 in the diﬀerent fractions
of the gradient revealed a signal for DGAT2 in the LD fraction, but no ACAT1 protein was
detected (ﬁgure 4.2). This shows that DGAT2 localizes directly to the surface of LDs and
not only to the ER compartment in their vicinity.
4.1.1.2. The activity of DGAT2 on LDs
The localization of DGAT2 to the surface of LDs, especially under fatty acid-rich conditions,
raised the question, whether this enzyme is functional in the catalysis of TAG formation
under these conditions. This activity would enable the LD to locally synthesize TAG, which
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Figure 4.2.: DGAT2 localizes to LDs
Lysates of cells transiently overexpressing DGAT2 or of untransfected control cells were subjected to sucrose density
gradient centrifugation. Fractions of the gradients were assayed by western blot analysis for expressed DGAT2 (lower
row) and for the endogenous ER marker protein ACAT1 (upper row), which serves both as a loading control and to
demonstrate absence of ER contamination from droplets.
might be advantageous for a fast response to excessive fatty acid supply. Additionally, it
might participate in the acylation of DAG that is stored within the LDs [28]. Therefore,
LDs isolated from wildtype or DGAT2-overexpressing COS7 cells were analyzed for their
capacity to synthesize TAG from DAG and acyl-CoA. The data show that isolated wildtype
LDs are capable to synthesize minor amounts of TAG. This LD-associated activity increases
strongly upon overexpression of DGAT2 (ﬁgure 4.3).
4.1.2. LPCAT1 and LPCAT2 catalyze the formation of PC on LDs
Besides TAG, the major lipid of LDs is PC, which forms a monolayer that surrounds the
TAG core. There are two possible pathways for the formation of PC. On the one hand it is
formed from DAG and CDP-choline by the so called de-novo or Kennedy pathway, on the
other hand it is formed from lyso-phosphatidylcholine (LPC) and acyl-CoA. This reaction is
catalyzed by lyso-phosphatidylcholine acyltransferases (LPCATs) and is part of the so-called
membrane-remodeling process or Lands cycle (see section 2.4). As shown in section 4.1.1,
LDs are able to locally synthesize TAG. The growth of the LD surface must be coordinated
with the growth of the LD core, suggesting a local mechanism for the synthesis of surface
Figure 4.3.: DGAT2 enables LDs to locally synthesize TAG
Lysates of cells transiently overexpressing DGAT2 or of untransfected control cells were subjected to sucrose density
gradient centrifugation. Samples of top fractions containing puriﬁed LDs and of bottom fractions (BF) were incubated
for 1 h with radiolabeled acyl-CoA in the presence or absence of DAG in the assay buﬀer as indicated. Lipids were
extracted and analyzed by TLC for radiolabeled TAG. Note that lanes 1-3 and 5-7 show triplicate measurements.
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lipids like shown in section 4.1.1 for the core lipids. In order to identify candidates for local
synthesis of PC on LDs the proteome of isolated LDs from A431 cells was dissected by
protein mass spectrometry (supplementary ﬁgure A.2 and supplementary table B.1). This
revealed the enzymes LPCAT1 and LPCAT2 as possible candidates.
4.1.2.1. Localization of LPCAT1 and LPCAT2
A speciﬁc antibody against human LPCAT1 and human LPCAT2 was raised by C. Thiele.
The antibodies are isoform speciﬁc and recognize endogenous proteins (supplementary ﬁgure
A.3). The western blot analysis of cell lysates from HuH7, A431 and COS7 cells revealed the
expression of LPCAT1 and LPCAT2 in A431 and COS7 cells and the expression of LPCAT1
in HuH7 cells (ﬁgure 4.4). While A431 cells express large amounts of both proteins, COS7
cells in comparison show weaker expression of both proteins and HuH7 cells express only
LPCAT1 in even lower amounts. The analysis of LPCAT1 and LPCAT2 localization in
A431 cells (ﬁgure 4.5 and ﬁgure 4.6) and COS7 cells (ﬁgure 4.7) revealed, besides a reticular
staining also a ring-like and patch-like staining pattern around LDs. These patterns were
independent of the nutritional status of the cell and most likely reﬂect the available amount
of both proteins. While in A431 cells the expression of large amounts of both proteins
results in localization in ring-like structures, the lower expression in COS7 cells results in
LD-associated patch-like structures. The amount of LPCAT1 in HuH7 cells was too low and
the protein too dispersed for a speciﬁc staining in immunoﬂuorescence.
Figure 4.4.: Expression of LPCAT1 and LPCAT2 in HuH7, A431 and COS7 cells
Total lysates of HuH7 cells, A431 cells and COS7 cells were subjected to SDS-PAGE/western blot for LPCAT1,
LPCAT2 and GAPDH (for normalization). Note that A431 cells contain abundant LPCAT1 and LPCAT2, whereas
HuH7 cells contain a small amount of LPCAT1, but no detectable LPCAT2. Longer exposure times do not reveal
any signal for LPCAT2 in HuH7 cells (data not shown).
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Figure 4.5.: Localization of LPCAT1 in A431 cells
A431 cells were cultivated for 20 h in DMEM supplemented with 10% of either delipidated FCS (DL), normal FCS
(FCS), or normal FCS + 100 휇M oleate (Ole). Cells were ﬁxed and processed for immunoﬂuorescence microscopy
using BODIPY 493/503 to stain neutral lipids (lipid droplets) and anti-LPCAT1 to stain the endogenous protein.
In the merged pictures, BODIPY 493/503 staining is in green, anti-LPCAT1 in red. Scalebar = 10 휇m.
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Figure 4.6.: Localization of LPCAT2 in A431 cells
A431 cells were cultivated for 20 h in DMEM supplemented with 10% of either delipidated FCS (DL), normal FCS
(FCS), or normal FCS + 100 휇M oleate (Ole). Cells were ﬁxed and processed for immunoﬂuorescence microscopy
using BODIPY 493/503 to stain neutral lipids (lipid droplets) and anti-LPCAT2 to stain the endogenous protein.
In the merged pictures, BODIPY 493/503 staining is in green, anti-LPCAT2 in red. Scalebar = 10 휇m.
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Figure 4.7.: Localization of LPCAT1 and LPCAT2 in COS7 cells
COS7 cells were cultivated for 20 h in DMEM supplemented with 10% normal FCS + 100 휇M oleate. Fixation,
staining and imaging were performed as described in ﬁgure 4.5 and 4.6. Scalebar = 10 휇m.
In order to distinguish whether LPCAT1 and LPCAT2 localize to the ER compartment at
the vicinity of LDs or directly to their surface, LDs were isolated from oleate-fed A431 and
HuH7 cells in a sucrose density gradient (see section 6.2.2.7). The western blot analysis of
the abundance of LPCAT1 and LPCAT2, the LD marker proteins ACSL3, TIP47, NSDHL
and ADRP and the ER membrane proteins ACAT1 and calnexin in the diﬀerent fractions
of the gradient revealed a signal for LPCAT1 and LPCAT2 and the LD marker proteins in
the LD fraction, but no or minor amounts of the ER markers calnexin and ACAT1 protein
were detected (ﬁgure 4.8). This shows that LPCAT1 and LPCAT2 localize directly to the
surface of LDs and not only to the ER compartment in their vicinity.
4.1.2.2. The activity of LPCAT1 and LPCAT2 on LDs
Similar to DGAT2 that enables LDs to locally synthesize TAG, LPCAT1 and LPCAT2
might enable LDs to locally synthesize PC. Therefore it was studied, whether LDs have the
ability to synthesize PC via LPCATs, whether this activity is speciﬁc for LDs and whether
it is a general property of LDs. LPCAT activity and LPAAT activity, which is abundant in
the ER [150], were compared in three diﬀerent cell lines (HuH7, COS7 and A431). While
25
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(a) HuH7 (b) A431
Figure 4.8.: LPCAT1 and LPCAT2 localize to LDs
Lysates of HuH7 cells (a) or A431 cells (b) that were grown in supplemented RPMI and DMEM with 10% FCS and
100 휇M oleate, repectively, were subjected to ﬂoatation in a sucrose density gradient. The gradient was fractionated
from the top into lipid droplets, intermediate, ﬂoating membrane, and bottom fractions.
(a) Proteins were analyzed by SDS-PAGE/western blot for LPCAT1, the known integral droplet proteins ACSL3
and NSDHL, the peripheral droplet proteins ADRP and TIP47 and the integral ER membrane proteins ACAT1 and
calnexin.
(b) Proteins were analyzed by SDS-PAGE/western blot for LPCAT1 and LPCAT2, the known integral droplet
proteins ACSL3 and NSDHL, the peripheral droplet protein TIP47 and the integral ER membrane proteins ACAT1
and calnexin.
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Figure 4.9.: LDs possess LPCAT activity
HuH7, COS7 and A431 cells were cultured in the presence of 100 휇M oleic acid for 16 h, lysed and the lysate
subjected to ﬂoatation in a sucrose density gradient. Cell lysates (lysate) or puriﬁed lipid droplets (LD) isolated
from the indicated cell lines were incubated in the presence of [3H]acyl-CoA and lyso-phosphatidylcholine (LPC) or
lyso-phosphatidic acid (LPA). Lipids were extracted and analyzed by TLC followed by autoradiography. Radioactive
spots were identiﬁed by co-migrating standards; PC, phosphatidylcholine; PA, phosphatidic acid. To calculate
enrichment of LPCAT activity on LDs, spots were scraped, lipids extracted and quantiﬁed by scintillation counting.
Enrichment was deﬁned as the ratio of radioactive PC/PA in the LDs, divided by the same ratio in the lysates.
cell lysates showed comparable LPCAT and LPAAT activities (ﬁgure 4.9, lanes 1+2, 5+6,
9+10), puriﬁed LDs displayed a much weaker activity for LPAAT, but a strong activity for
LPCAT (4.9, lanes 3+4, 7+8, 11+12), resulting in an enrichment of LPCAT activity relative
to LPAAT activity of about 9- to 15-fold.
As LPCAT1 and LPCAT2 localize to LDs, it is likely that the measured LPCAT activity
relies on these proteins. Similar to the DGAT activity on LDs (section 4.1.1.2), overex-
pression of LPCAT1 or LPCAT2 in A431 cells increased LPCAT activity on isolated LDs:
17±12-fold (p < 0.05, n = 5) for LPCAT1 and 2.9±1.8-fold (p < 0.1, n = 5) for LPCAT2
overexpression.
Though only enzymes for PC synthesis by the Lands cycle were identiﬁed by protein mass
spectrometry of isolated LDs (supplementary table B.1), it is possible that LDs also use
the Kennedy pathway for local synthesis of PC. The amount of these enzymes on the LD
might be too low to be identiﬁed by mass spectrometry or the localization of these enzymes
to LDs might be transient and less stable than the localization of LPCAT1 and LPCAT2.
By radioactive labeling combined with the measurement of the product from the enzyme
reaction, higher sensitivity for detection is achieved than could be reached by direct detection
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Figure 4.10.: LDs locally synthesize PC by the Lands cycle
A431 cells were cultured in the presence of 100 휇M oleic acid for 16 h, lysed and the lysate subjected to ﬂoatation in a
sucrose density gradient. Samples of the lipid droplet fraction (LD), the ﬂoating membrane fraction (membranes), and
the total lysates (lysate) of A431 cells were incubated in the presence of either [14C]CDP-choline plus diacylglycerol
(left panel, CPT assay) or of [3H]acyl-CoA and LPC (right panel, LPCAT assay). Lipids were extracted and
analyzed by TLC followed by autoradiography. Radioactive spots were identiﬁed by co-migrating standards. PC,
phosphatidylcholine; FFA, free fatty acid.
of the enzyme. Therefore, LDs isolated from A431 cells were incubated with radioactively
labeled substrates for the Lands cycle or for the Kennedy pathway. While lysates and
membrane fractions displayed both CPT and LPCAT activity (ﬁgure 4.10, lanes 4, 5 and
9, 10), puriﬁed LDs showed only a strong LPCAT activity (ﬁgure 4.10, lanes 6, 7), but no
signiﬁcant CPT activity (ﬁgure 4.10, lanes 1, 2). Altogether, the experiments demonstrate
that LPCAT activity on LDs is speciﬁc and general, and is not due to contamination by ER
membranes.
4.2. Physiological role of LPCAT activities
This section presents the ﬁrst evidence that the LD activities of LPCAT1 and LPCAT2 are
reﬂected in the PC proﬁle of LDs. Additionally, LPCAT1 and LPCAT2 participate in the
adaptation and formation of the LD surface monolayer. Furthermore, evidence is presented
that they inﬂuences the proper secretion of lipids from cells.
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4.2.1. LPCAT1 and LPCAT2 participate in the synthesis of the LD surface
Though several enzymes catalyze the same reaction, they often show diﬀerent substrate
preferences. If the local activity of LPCAT1 and LPCAT2 contribute to the synthesis of the
PC of the LD surface monolayer, their substrate preference should be reﬂected in the LD
surface PC proﬁle. Thus, they would participate in the formation of an organelle-speciﬁc
composition of molecular PC species of the LD surface monolayer, which distinguishes it
from the membranes of other cellular organelles. To characterize the molecular lipid com-
position of the LD surface monolayer we performed a comparative lipidomic analysis. For
this experiment, it was necessary to obtain droplets with suﬃcient size for ﬂoatation without
supplementation of oleic acid, which otherwise would dominate the lipid species composition.
Therefore, A431 cells were grown with horse serum as a lipid donor. LDs were ﬂoated in a
modiﬁed sucrose gradient (section 6.2.2.7 and [9]) to remove unspeciﬁc LD-associated mem-
brane fragments and proteins. Western blots of the gradient fractions demonstrated that the
LD preparation was enriched in integral LD proteins and devoid of plasma membrane, ER
and endosomal contaminations (data not shown). The purity was further conﬁrmed by mass
spectrometry that showed an almost complete separation of TAG and PC in the LDs and the
ﬂoating membrane fraction, respectively (supplementary ﬁgure A.4). Next, the molecular
composition of the phosphocholine-containing lipids, PC and sphingomyelin (SM), in cell
lysates, ﬂoating membranes and LDs were determined by lipid mass spectrometry (section
6.2.3.4).
LDs were enriched in PC species with saturated and mono-unsaturated fatty acid moieties
(PC 28:0, 30:0, 32:0, 34:1, 34:2, 36:1, 36:2) as compared to ﬂoating membranes and cell
lysates (ﬁgure 4.11). In contrast, PC species with poly-unsaturated fatty acid moieties
(= 3 double bonds, e.g. PC 38:4), ether PC species and SM species were depleted from
LDs (ﬁgure 4.11 insert). LPCAT1 has a substrate preference for medium-chain saturated
LPC and for medium- and long-chain saturated fatty acids especially palmitate, but it uses
also unsaturated C18 [106, 107]. LPCAT2 has a substrate preference for oleoyl-LPC and
palmitoyl-LPC and short- and medium-chain saturated and C18 unsaturated fatty acids
[108]. In conclusion, the PC proﬁle of the LD monolayer reﬂects the substrate preferences
of LPCAT1 [106, 107] and LPCAT2 [108]. However, a part of the LD PC proﬁle also ﬁts to
the recently described substrate preferences of the ER-associated LPCAT3 [117, 118].
In comparison to the LD lipid proﬁle of CHO-K2 cells [29] and of HepG2 cells [8], the
surface of LDs from A431 cells is more similar to HepG2 than to CHO-K2 cells. The LD
surface lipid composition of CHO-K2 cells resembles other cellular membranes except an
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Figure 4.11.: Isolated LDs have a unique surface lipid proﬁle
A431 cells were grown in DMEM with 10% normal FCS and additional 20% horse serum for 24 h. LDs were isolated
in a modiﬁed sucrose gradient containing a pH 11.0 layer to remove all traces of LD-attached proteins and membrane
fragments. Cell lysates, LDs and ﬂoating membrane fractions were collected. Total lipid extracts were analyzed in
positive ion mode by precursor ions scanning for the fragment ion of phosphocholine (m/z 184.1), which speciﬁcally
detects PC and SM. The amount of each lipid species is presented as percent normalized to the total abundance of PCs
and SMs in each of the separate analysis. The insert shows the abundance of PC species with the indicated number of
double bonds (db), as percent of total PC in the respective fraction. Bars coloured in amber, blue and red designate
species detected in LD, ﬂoating membranes and whole cell lyzate samples. PC, ester-linked phosphatidylcholine; PC
O, ether-linked phosphatidylcholine; SM, sphingomyelin. Numbers indicate the total number of carbon atoms:double
bonds in the fatty acid or fatty alcohol moities. This ﬁgure is provided by Christer Ejsing.
30
4.2. Physiological role of LPCAT activities
enrichment for PC, LPC and lyso-phosphatidylethanolamine (LPE) and a depletion for SM
and phosphatidylserine (PS). In contrast, the lipid composition diﬀers between LDs and ER
or PM in HepG2 and also in A431 cells. While the PC of the LD surface of HepG2 cells
was reported to be mainly enriched in mono-unsaturated fatty acids, the PC of LDs of A431
cells is also enriched in some saturated fatty acids compared to microsomal membranes and
whole cell lysates.
4.2.2. LPCAT1 and LPCAT2 inﬂuence the morphology of LDs
The ability of LDs to synthesize their core lipid TAG and their surface lipid PC (section 4.1)
might be beneﬁcial for a fast adaptation to changes in the nutritional status. Concerning
lipogenesis and lipolysis, the size of the LDs becomes an important factor. The same amount
of TAG can be stored either in many small LDs or in few large LDs. Smaller droplets have
a larger surface-to-volume ratio. This enables more lipid anabolic or catabolic enzymes to
localize to the LD, enhancing the formation or degradation of lipids. The availability of sur-
face and core material by the local activities of the LD will inﬂuence the surface-to-volume
ratio of the LD. If local production of PC by LPCAT1 and LPCAT2 is functionally impor-
tant for the dynamics of the LD monolayer, manipulation of LPCAT activity may result in a
phenotypic alteration of the cellular LD pool. Therefore, siRNA-mediated gene silencing of
LPCAT1 and LPCAT2 was performed in A431 cells followed by microscopic imaging of LDs.
Figure 4.12.: Silencing of LPCAT1 and LPCAT2 by siRNA reduces the amount of the respective
proteins in A431 cells
A431 cells were grown in DMEM with 10% normal FCS and were either left untreated (untreated or wt), mock trans-
fected (mock), transfected with control siRNA (eg5 as transfection control, leads to cell death, or scrambled#5+#6
as non-targeting siRNAs) or the four possible combinations of two sequences each against LPCAT1 or LPCAT2 as
indicated. After 48 h incubation in DMEM with normal FCS, cells were lysed and subjected to SDS-PAGE/western
blot for LPCAT1, LPCAT2 and glycerol-3-phosphate dehydrogenase (GAPDH, as a loading control).
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Figure 4.14.: Silencing of LPCAT1 and LPCAT2 by siRNA increases the mean size of LDs in A431
cells signiﬁcantly
Confocal images as described in ﬁgure 4.13 from three diﬀerent experiments were quantiﬁed with Image J and the
mean LD size from the LD size distribution is compared between controls and double knock-downs as described
in ﬁgure 4.12. Signiﬁcances were calculated by unpaired two-sided t-test analysis relative to scrambled#5+#6 and
standard deviation is shown for each dataset.
Double knock-down of LPCAT1 and LPCAT2 with various combinations of siRNA sequences
results in a decrease of LPCAT1 and LPCAT2 proteins compared to controls (ﬁgure 4.12).
In the LPCAT1-LPCAT2 double knock-down cells, LDs are slightly enlarged (ﬁgure 4.13).
Quantiﬁcation of these images conﬁrms a signiﬁcant increase in mean LD size upon LPCAT1-
LPCAT2 knockdown (ﬁgure 4.14 and supplementary table B.2). However, there is no in-
crease in the rate of TAG synthesis as measured by [3H]oleate-labeling (supplementary ﬁgure
A.5), nor in the total TAG content of the cells as determined by mass spectrometry (sup-
plementary ﬁgure A.6). In addition, the abundance of other neutral lipids (DAG, CE) and
phospholipids (PC, PE and SM) is unaﬀected.
To corroborate the observed increase in LD diameter, the siRNA knock-down experiment
was repeated under modiﬁed conditions. The cells were kept under choline-free conditions
during the knock-down. This limits PC biosynthesis, leading to channeling of fatty acids
towards the production of TAG, as described for the inhibition of the pathway for de novo
PC synthesis (supplementary ﬁgure A.7 and [151]). Although these experimental conditions
lead to overall larger LDs, the knock-down of LPCAT1 and LPCAT2 results in a further
increase of LD size (supplementary ﬁgure A.8) without changes in TAG biosynthetic rates
(supplementary ﬁgure A.9) or total TAG amount (supplementary ﬁgure A.10). This shows
that the increase in LD size upon knock-down of LPCAT1-LPCAT2 results from another
mechanism, than the LD size increase following choline-depletion. Nevertheless, the LD
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Figure 4.15.: Silencing of LPCAT1 in HuH7 cells reduces cellular LPCAT1 protein and activity
HuH7 cells were grown in supplemented RPMI medium with 10% normal FCS and were either left untreated (un-
treated or wt), mock transfected (mock), transfected with control siRNA (scrambled#5 and scrambled#6 as non-
targeting siRNAs) or the two diﬀerent siRNA sequences against LPCAT1 as indicated. After 72 h incubation in
supplemented RPMI with normal FCS, cells were scraped and subjected to a LPCAT activity assay or lysed and
subjected to SDS-PAGE/western blot for LPCAT1 and GAPDH (loading control).
size increase upon LPCAT1-LPCAT2 knock-down is weak due to partial compensation of
the iso-enzymes (data not shown) and insuﬃcient reduction of the LPCAT1 and LPCAT2
proteins.
Therefore, results were conﬁrmed in the human hepatoma cell line HuH7 and in vivo in
the model organism Drosophila melanogaster. In contrast to A431 and COS7 cells, HuH7
cells express detectable amounts of LPCAT1 only, but no LPCAT2 (ﬁgure 4.4). Similarly,
LPCAT1 is associated with LDs (ﬁgure 4.8). Knock-down of LPCAT1 in HuH7 cells with two
diﬀerent siRNA sequences results in a decreased LPCAT activity in whole cell lysates and in
a remarkable decrease in LPCAT1 protein (ﬁgure 4.15). Morphologically, this knock-down
results in the appearance of larger LDs (ﬁgure 4.16). A quantiﬁcation of the microscopic
images revealed a signiﬁcant increase in the mean LD size upon LPCAT1 knock-down of
about 100 - 200 nm2 (ﬁgure 4.17 and supplementary table B.3). This increase is due to a
shift from small LDs (50 - 300 nm2) to large LDs (400 nm2 - >1 휇m2) (ﬁgure 4.18). Similar
to A431 cells, the increase in LD size upon LPCAT1 knock-down is neither caused by an
increase in TAG synthesis rate (ﬁgure 4.19) nor is it based on an enhanced accumulation of
neutral lipids (ﬁgure 4.20).
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Figure 4.17.: Silencing of LPCAT1 by siRNA increases the mean size of LDs in HuH7 cells signiﬁcantly
Confocal images as described in ﬁgure 4.16 from three diﬀerent experiments were quantiﬁed with Image J and the
mean LD size from the LD size distribution is compared between controls and knock-down as described in ﬁgure
4.15. Signiﬁcances were calculated by unpaired two-sided t-test analysis relative to wt and standard deviation is
shown for each dataset.
Figure 4.18.: Changes in LD size distribution in HuH7 cells upon LPCAT1 knock-down
Confocal images as described in ﬁgure 4.16 from three diﬀerent experiments were quantiﬁed with Image J and the LD
size distribution is displayed as percentage of total LDs analyzed per treatment. Measured LDs were grouped into
size classes displayed as LD size in 휇m2. Controls (black, light and dark grey and white), siRNAs against LPCAT1
(red, blue)
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Figure 4.19.: Knock-down of LPCAT1 in HuH7 cells has no inﬂuence on TAG synthesis rate
HuH7 cells were grown and transfected with siRNA as described in ﬁgure 4.15. [3H]oleate was added for further 24 h
to the cells either directly (1.day), 24 h (2.day) or 48 h (3.day) after transfection. Lipids were extracted, separated
by TLC and visualized by autoradiography. Only the region of newly synthesized [3H]TAG is shown.
Figure 4.20.: Silencing of LPCAT1 in HuH7 cells does not inﬂuence the amount of stored neutral
lipids
HuH7 cells were transfected as described in ﬁgure 4.15. After 72 h, total lipid extracts were analyzed by mass
spectrometry. Each sample was measured in duplicate, and species abundances were normalized to the corresponding
internal standard. The molar contents of each species of the same class were summed up and normalized to the total
content of all detectable lipids. This diagram and lipid mass spectrometry is provided by Christer Ejsing.
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The LPCAT activity is not only important for LDs in isolated cell lines, but also seems
to play a role within complex organisms. LPCAT1 and LPCAT2 have one homologue in
Drosophila melanogaster, which is annotated as CG32699 and is predicted to be a LPC
acyltransferase. The investigation of three knockout strains, which harbor three diﬀerent
P-elements in the 5’-UTR region of CG32699 for silencing in a white mutant background,
conﬁrmed the inﬂuence of LPCAT activity on the size of LDs. LDs in the fat body [152] of
L3 larvae of these knockout strains are larger than the LDs in the comparable white mutant
or wildtype ﬂy larvae (ﬁgure 4.21). Additionally, crosses between these knockout strains
exclude an inﬂuence of the P-elements on the LD phenotype (supplementary ﬁgure A.11).
4.2.3. LPCAT1 is important for lipoprotein particle secretion
Since LDs serve as energy storage organelles, their functionality, morphology and compo-
sition inﬂuences both cell and systemic energy metabolism [93]. From the intestine and
the liver, TAG, CE and phospholipids are transported by lipoprotein particles to adipose
tissues and muscles. It was reported that HuH7 cells synthesize and secrete apoB contain-
ing VLDL and LDL particles (supplementary ﬁgure A.12, [124], [134] and [153]) and that
their assembly requires the long-chain acyl-CoA synthetase ACSL3 [77]. This protein is
also involved in the incorporation of fatty acids into PC in this cell line and localizes to
LDs [76]. Since LPCAT1 and LPCAT2 localize to LDs and catalyze PC synthesis, they
might also be important for lipoprotein assembly and secretion. Therefore, the secretion
of apolipoproteinB (apoB) containing lipoprotein particles from HuH7 cells was measured,
quantifying the amount of secreted apoB, which is associated with lipoprotein particles of a
similar density as LDL (supplementary ﬁgure A.12). As HuH7 cells contain LPCAT3 [110]
and LPCAT1, but no LPCAT2 (ﬁgure 4.4), only LPCAT1-speciﬁc siRNAs were used for
knock-down. The knock-down with two distinct siRNAs resulted in a signiﬁcant reduction
of apoB-containing lipoprotein particle secretion (ﬁgure 4.22a and b) monitored by western
blot and ELISA. Furthermore, the knock-down of LPCAT1 results in a decreased release of
[3H]labeled lipids from HuH7 cells (ﬁgure 4.22c), which indicates that, in connection to re-
duced apoB secretion, less lipoprotein particles are secreted. Nevertheless, the reduction of
secreted lipids seems to be caused mainly by reduced secretion of neutral lipids (for lipid pro-
ﬁle see supplementary ﬁgure A.13). As hepatitis C virus (HCV) relies on lipoprotein particle
release to exit hepatocytes [154], virus replication and release was analyzed upon LPCAT1
knock-down. LPCAT1 knock-down did not inﬂuence virus replication (data not shown),
but one LPCAT1 siRNA sequence signiﬁcantly reduces HCV release from transfected HuH7
cells (ﬁgure 4.22d), corroborating the connection between LPCAT1 and lipoprotein particle
secretion.
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(a) Secretion of apoB (WB) (b) Secretion of apoB (ELISA)
(c) Secretion of lipid (d) Secretion of HCV
Figure 4.22.: LPCAT1 is important for lipoprotein particle secretion in HuH7 hepatoma cells
HuH7 cells were grown in serum-free medium and transfected with non-targeting siRNA (control) or one of two
diﬀerent siRNA sequences targeting LPCAT1.
(a) After 72 h, supernatants and cell lysates were collected and subjected to SDS-PAGE/western blot (WB). Su-
pernatants were analyzed for apolipoproteinB, cell lysates for GAPDH and LPCAT1. Secreted apoB and cellular
LPCAT1 were ﬁrst normalized to GAPDH and then to control. The panel shows the mean result of ﬁve experiments;
dark grey, apolipoproteinB; light grey, LPCAT1.
(b)After 24 h siRNA was removed and cells were grown for further 48 h in fresh serum-free medium. Supernatants
were analyzed for apolipoproteinB with an apoB speciﬁc ELISA. Cells were collected and protein content was mea-
sured. ApoB released was normalized to the protein content and then to control. The panel shows the mean results
of four experiments.
(c) The siRNA transfected cells were labeled with [3H]oleate for 24 h. Then, radioactivity and siRNAs were re-
moved and cells were grown for further 48 h in fresh serum-free medium. Lipids of supernatant (S) and cells (C)
were extracted and quantiﬁed by scintillation counting. The ratio between secreted radioactive lipid (S) and total
radioactively labeled lipid (S + C) was normalized to control. The panel shows the mean results of four experiments.
(d) HuH7.5 ﬁreﬂy cells were transfected with siRNA for 24 h and then medium was replaced by fresh medium for
40 h. Next, cells were infected with Jc2Ra reporter hepatitis C virus (HCV) at MOI 0.21 for 24 h. The medium was
replaced by fresh medium and 48 h later supernatants were collected and used for reinfection of HuH7 cells. HuH7
cells were lysed and assayed for Renilla Luciferase activity, to calculate the levels of HCV assembly/release. ApoE
targeting siRNA was used as control for disruption of VLDL assembly/secretion; PI4Ka siRNA was used as control
for HCV replication. The mean values of three independent experiments are shown. The analysis of HCV replication
and secretion (d) is provided by Gualtiero Alvisi.
In all four subﬁgures the standard deviations are shown and the p-values were obtained by unpaired t-test, indicating
the signiﬁcance relative to the respective control.
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4.3. Monotopic topology is a common feature of LD membrane
proteins
In this section the topology of LD-localizing membrane proteins is investigated and compared
to a typical single-span ER membrane protein. Though several membrane proteins were
reported to localize to LDs and several proteins with monotopic conformation were described,
it is still not clear to which extent the topology inﬂuences LD localization.
The comparison of the protein sequence of LPCAT1, LPCAT2 and DGAT2 with the typical
LD-localizing membrane proteins NSDHL and caveolin 1 and the typical ER single-span
membrane protein calnexin reveals a long hydrophobic stretch in the LD-localizing proteins
(ﬁgure 4.23). This stretch spans about twice the length (about 35 amino acids) of the
hydrophobic membrane domain of single-span membrane proteins (15 to 25 amino acids)
and it is suﬃcient to pass a membrane two times. The middle of this domain is marked by a
charged, small or helix-breaking amino acid that may force a kink into the structure. Thus,
the features of the LD-localizing membrane proteins point towards a monotopic hairpin
conformation. Additionally, all of these proteins display complex multiple localizations to
LDs and other cellular organelles [28, 155–158].
In NSDHL [159] and caveolin 1 [160] the long hydrophobic domain does not fully span
a membrane, but forms a turn with both N- and C-terminus facing the cytoplasm. This
monotopic mode of membrane insertion allows protein integration into the surface monolayer
of LDs [161] and explains, how membrane proteins can localize to a phospholipid bilayer
like the ER membrane and at the same time to a phospholipid monolayer surrounding
a hydrophobic core like LDs (see ﬁgure 4.1 and ﬁgure 4.6). Furthermore, in comparison
to calnexin, the LD-localizing membrane proteins show no typical ER localizing sequence,
although they also localize to the ER. It has to be mentioned that some LD-localizing
proteins contain a C-terminal KKXX-ER-retrieval motif that seems to positively inﬂuence
LD localization [157]. Also phosphorylation can be involved in LD targeting, as Nir2 is
targeted to LDs upon phosphorylation on a threonine [162].
As described in section 2.3 and 2.4 many reactions are catalyzed by diﬀerent iso-enzymes,
which belong to diﬀerent protein families and diﬀer in protein sequence and structure.
Though some proteins like the AAM-B methyltransferase contain a N-terminal hydrophobic
sequence that seems to be crucial to target these proteins to LDs [163], this sequence motif is
not common to all LD-localizing proteins and is lacking in LPCAT1, LPCAT2 and DGAT2.
A more widespread feature of LD-localizing proteins is the existence of hydrophobic do-
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Figure 4.23.: LD-localizing membrane proteins contain a long hydrophobic stretch
Sequence comparison between the single long hydrophobic sequences of LPCAT1, LPCAT2 and DGAT2 and the
hairpin hydrophobic domains of the well-characterized LD proteins, NSDHL and caveolin 1 (CAV1) and the ER
transmembrane protein calnexin (CALX). The LD monotopic membrane proteins have a single long hydrophobic
sequence with regular interspaced helix-breaking amino acids and lack N-terminal hydrophobic leucine-rich signal
sequences. Position 1 indicates the ﬁrst residue of the hydrophobic stretch or the N-terminal methionine. Color
code in the membrane domains: charged residues (blue), helix breaking (P,G,S,C)(red); color code for N-termini:
charged residues (blue), leucine (green). Sequences are taken from Swissprot with the following accession numbers:
LPCAT1 Q8NF37, LPCAT2 Q7L5N7, DGAT2 Q96PD, NSDHL Q15738, CAV1 Q03135, CALX P27842. This ﬁgure
is provided by Christoph Thiele.
mains, with which the cytosolic PAT family proteins can attach to LDs [164, 165] or integral
proteins can insert into LDs (ﬁgure 4.23). The integral membrane proteins of LDs show a
monotopic, presumably hairpin, topology that might selectively target some iso-enzymes to
LDs.
4.3.1. Topology of LPCAT1 and LPCAT2
The hydrophobicity plots of both LPCAT1 and LPCAT2 show a strongly hydrophobic region
starting at amino acid position 44 in LPCAT1 and 58 in LPCAT2 (supplementary ﬁgure
A.14). This region is predicted to form a hairpin (TTHM prediction Expasy) so that both
proteins should be inserted into membranes with both termini targeting the cytosol. To
characterize the topology of LPCAT1 and LPCAT2, fusion constructs with either a N- or
C-terminal 3HA-tag were expressed. Cells were permeabilized using saponin (permeabilizes
all cellular membranes) or digitonin (permeabilizes the plasma membrane, but not the ER
membrane) [166] and stained with anti-HA antibody to detect the termini of the expressed
LPCAT proteins, and an antibody against the lumenal ER protein disulﬁde isomerase (PDI)
to monitor the selective permeabilization of the plasma membrane by digitonin. While anti-
HA detected the LPCAT constructs irrespective of the mode of permeabilization or the
position of the tag, the anti-PDI only showed speciﬁc staining after saponin permeabiliza-
tion (ﬁgure 4.24). This result indicates that both termini of LPCAT1 and LPCAT2 are
directed towards the cytoplasm.
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This was conﬁrmed in a biochemical analysis. A431 cells were transfected with N-terminally
3HA-tagged LPCAT1 or LPCAT2, and microsomes were isolated and treated with proteinase
K. The integrity of the microsomes was analyzed with the antibody against PDI. The acces-
sibility of the N-terminus of LPCAT1 and LPCAT2 towards proteinase K was detected by
anti-HA antibody, the accessibility to the C-terminus by our speciﬁc LPCAT1 and LPCAT2
antibodies. Though microsomes remained mainly intact after the isolation and digestion pro-
cedure, the signal of both LPCAT1 and LPCAT2 termini vanished or was strongly reduced
after proteinase K digestion (ﬁgure 4.25). In conclusion, LPCAT1 and LPCAT2 display a
monotopic conformation with both termini facing the cytoplasm.
4.3.2. Topology of DGAT2
DGAT2 contains a hydrophobic stretch of about 46 amino acids starting at amino acid 67.
The properties and length of the transmembrane domain is similar to caveolin 1 (ﬁgure 4.23)
and is very conserved in diﬀerent species (ﬁgure 4.29). Caveolin 1 predominantly localizes to
the plasma membrane and it can bind free cholesterol. LD-targeting of caveolins is achieved
by overexpression, BrefeldinA treatment, insertion of a KKXX-ER-retrieval sequence or
deletions in the N-terminus [157, 158, 167]. It has been shown that caveolin is inserted into
the membrane in a hairpin topology and that both termini face the cytoplasm [160].
If DGAT2 is also a monotopic hairpin membrane protein like caveolin 1 with both termini
directed towards the cytoplasm, tags at both termini of DGAT2 must be detectable by
antibodies, even though the ER lumen is not accessible. Therefore, similar fusion constructs
as described for LPCAT1 and LPCAT2 (section 4.3.1) were cloned for DGAT2 with either
a N- or C-terminal 3HA-tag. These constructs were expressed in COS7 cells, which were
permeabilized using saponin or digitonin [166] and stained with anti-HA antibody to detect
expressed DGAT2 protein, and an antibody against the lumenal ER protein PDI. While
anti-HA detected the DGAT2 construct irrespective of the mode of permeabilization or the
position of the tag, the anti-PDI only showed speciﬁc staining after saponin permeabilization
(ﬁgure 4.26). This result indicates that both termini of DGAT2 are directed towards the
cytoplasm like it was shown for LPCAT1 and LPCAT2 in section 4.3.1.
This was conﬁrmed in a biochemical analysis. COS7 cells were transfected with N- or C-
terminally 3HA-tagged DGAT2, and microsomes were isolated and treated with proteinase
K. The integrity of the microsomes was analyzed with the antibody against PDI. The acces-
sibility of the termini of DGAT2 towards proteinase K was detected by anti-HA antibody
and the digestion pattern was compared to the C-terminally 3HA-tagged hairpin protein
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Figure 4.24.: LPCAT1 and LPCAT2 insert into LDs and membranes in a monotopic conformation
A431 cells were transfected with vectors coding for LPCAT1 or LPCAT2 as indicated, both with either N-terminal
3HA-tag (HA-LPCAT) or C-terminal 3HA-tag (LPCAT-HA) and were cultivated for 16 hours in the presence of
100 휇M oleate. Cells were ﬁxed and processed for immunoﬂuorescence microscopy using either saponin (permeabilizes
all membranes) or digitonin (permeabilizes plasma membrane, but not the ER membrane) for permeabilization. Cells
were stained with BODIPY 493/503 to stain LDs (green), anti-HA to detect transfected LPCAT proteins (red) and
anti-PDI (blue) as a lumenal ER marker. Only merged pictures are shown. Note that LPCAT proteins are stained
irrespective of the position of the tag or the detergent used for permeabilization. In contrast, the luminal PDI epitope
is stained only after saponin permeabilization. See supplementary ﬁgure A.15 and A.16 for pictures split into the
single channels.
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Figure 4.25.: LPCAT1 and LPCAT2 insert into membranes in a monotopic conformation
N-terminally 3HA-tagged LPCAT1 or LPCAT2 were expressed in A431 cells for 16 h. Cells were cracked and
microsomes were collected by centrifugation. Microsomes were incubated in PBS with either no addition (negative
digestion control), addition of 1% Triton-X100 and proteinase K (positive digestion control) or addition of proteinase
K alone. The integrity of the microsomes was analyzed by western blot with the luminal ER marker PDI, the N-
terminus of LPCAT1 and LPCAT2 was detected with a HA-speciﬁc antibody (HA-tag) and the C-terminus with our
speciﬁc LPCAT1 and LPCAT2 antibodies (LPCAT). Note that either end of the protein is destroyed in the absence
of detergent. No smaller fragments were detected on the blots (data not shown).
caveolin 1. Though microsomes remained mainly intact after the isolation and digestion
procedure, the signal of both termini of DGAT2 vanished after proteinase K digestion simi-
lar as to caveolin 1 (ﬁgure 4.27). In conclusion, DGAT2 displays a monotopic conformation
with both termini facing the cytoplasm. This data are in line with a study to DGAT2
topology by Stone et al. [92] and Shockey et al. [168].
In order to corroborate that the monotopic conformation reﬂects a hairpin protein that in-
serts into the membrane rather than a strongly membrane-associated, but peripheral mem-
brane protein, the mode of membrane association was assayed in COS7 cells overexpressing
DGAT2. Therefore, membranes were isolated and incubated with high NaCl concentrations
or carbonate to disrupt electrostatic membrane interaction, with urea to disrupt structural
interaction of peripheral membrane proteins, with the detergents TritonX-100 or dodecyl-
maltoside to disrupt the membranes or with PBS as control. The analysis by western blot
of the diﬀerently treated membrane pellets and the corresponding supernatants reveals that
DGAT2 can be totally released from membranes only by treatment with detergents, that also
release the single-span membrane protein calnexin (ﬁgure 4.28). This shows that DGAT2
integrates into the membrane.
4.4. Regulation of DGAT2 localization and activity
In this section the TAG metabolism is further investigated regarding the regulation of
DGAT2 by interacting proteins. It is shown that DGAT2 interacts with the enzyme ACSL1
and that these proteins inﬂuence the cellular packaging of TAG.
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Figure 4.26.: Topology of DGAT2
COS7 cells were transfected with vectors coding for human DGAT2 with either N-terminal 3HA-tag (HA-DGAT2) or
C-terminal 3HA-tag (DGAT2-HA). Cells were ﬁxed and processed for immunoﬂuorescence microscopy using either
saponin (permeabilizes all membranes) or digitonin (permeabilizes plasma membrane, but not the ER membrane) for
permeabilization. Cells were stained with anti-HA to detect transfected DGAT2 protein (green) and anti-PDI (red)
as a lumenal ER marker. Note that DGAT2 protein is stained irrespective of the position of the tag or the detergent
used for permeabilization. In contrast, the luminal PDI epitope is stained only after saponin permeabilization.
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Figure 4.27.: DGAT2 is a monotopic membrane protein
N-terminally and C-terminally 3HA-tagged DGAT2 together with C-terminally 3HA-tagged Caveolin1 were expressed
in COS7 cells for 16 h. Cells were cracked and microsomes were collected by centrifugation. Microsomes were
incubated in PBS with either no addition (negative digestion control), addition of 1% Triton-X100 and proteinase
K (positive digestion control) or addition of proteinase K alone. The integrity of the microsomes was analyzed by
western blot with the luminal ER marker PDI, the N- and C-terminus of DGAT2 was detected with a HA-speciﬁc
antibody and compared to the signal of the HA-tag of the known monotopic membrane protein Caveolin1. Note that
either end of the protein is destroyed in the absence of detergent. No smaller fragments were detected on the blots
(data not shown).
Figure 4.28.: DGAT2 behaves like a single-span membrane protein
DGAT2 was expressed in COS7 cells for 16 h. Cells were cracked (Homogenate), crude membranes and nuclei were
pelleted (600xg P and 600xg S; P = pellet, S = supernatant) and membranes were collected by centrifugation (P1 and
S1). Membranes were incubated with PBS (PBS), 1% TritonX-100 in PBS (TritonX-100), 1% dodecylmaltoside in
PBS (DDM), 1 M NaCl in PBS (NaCl), 0.1 M Sodiumcarbonate in PBS (CO3) pH 11 and 6 M Urea in PBS (Urea).
Membranes were again collected by centrifugation and the abundance of DGAT2 in the pellet and the corresponding
supernatant was analyzed by western blot and compared to the single-span membrane protein Calnexin. The red
square marks the conditions under which DGAT2 is totally released from membranes.
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Figure 4.29.: Domain structure and conservation of DGAT2
Protein sequences of DGAT2 from diﬀerent species were aligned with ClustalW. The upper part describes the domains
of human DGAT2, which are representative for all DGAT2 from diﬀerent species, and highlights the catalytic motif,
which is conserved to 100%.
The middle part displays the sequence alignment of the N-terminal part of DGAT2 from diﬀerent species. Sequences
from mouse (MOUSE), human (HUMAN), rat (RAT), zebraﬁsh (DANRE), xenopus (XENTR and XENLA), bovine
(BOVIN), dictyostelium (DICDI), fungus (UMBRA) and ricinus plant (RICCO) were used for the alignment. The
numbering of amino acid position refers to the human DGAT2 protein sequence.
The lower part displays the vertebrate sequences and the coloured numbering of amino acid position refers to the
sequences in the same colour. Absolute conserved residues are marked by stars, highly conserved residues by colons.
The red boxes mark potential binding motifs for DGAT2-ACSL1 interaction calculated with hmmer. This ﬁgure is
provided by Anne Tuukkanen.
As DGAT2 plays an important role in the synthesis of the storage lipid TAG and is linked
to LDs, it is of growing interest to obtain a deeper knowledge of the regulation of DGAT2
and its connection to the lipid homeostasis of the cell. The localization of DGAT2 seems to
be subject to regulation. Figure 4.1 shows a change in localization from the ER membrane
to the LD surface in oleate-rich conditions. This change in localization might directly or
indirectly inﬂuence the activity of DGAT2. The localization and activity of DGAT2 might
be regulated by direct modiﬁcations like phosphorylation and ubiquitination or it could be
controlled by the interaction with other proteins.
Proteins interact with each other via speciﬁc binding motifs. These motifs are often very
conserved across diﬀerent species. DGAT2 is structured into three domains: the N-terminus,
the membrane domain (see ﬁgure 4.23) and the C-terminal catalytic domain (ﬁgure 4.29).
Though the N-terminus lacks an obvious function, the amino acid sequence is conserved be-
tween diﬀerent species, which makes it a good candidate as binding site for other proteins.
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4.4.1. DGAT2 interacts with ACSL1
Besides very transient interactions with modifying proteins like kinases, enzymes can be part
of multi-enzyme complexes [169]. Enzymatic activities that belong to the same metabolic
pathway often cluster in the same cellular locations, like the enzymes for cholesterol biogen-
esis [159]. Especially in multi-step reactions, this might lead to a faster and more eﬃcient
use of substrates to yield a certain end product [170]. Additionally, these complexes can
interact with activating or repressing proteins to eﬃciently activate or deactivate a complete
metabolic pathway instead of all the single participating enzymes.
4.4.1.1. Identiﬁcation of DGAT2 interaction partner
The structural analysis and the comparison of DGAT2 sequences of diﬀerent organisms
(ﬁgure 4.29) revealed that the N-terminal part of DGAT2 contains a highly conserved hy-
drophobic motif that might function as recognition and binding site for interaction partners.
In order to ﬁnd an interaction partner of DGAT2, the ﬁrst 66 amino acids of human DGAT2
were coupled to an SBP (Streptavidin Binding Protein)-tag (ﬁgure 4.30a) and after bacterial
expression of the construct at conditions to obtain natively folded protein, it was puriﬁed on
a streptavidin-sepharose column (see section 6.2.3.6). EGFP coupled to the same tag was
used in parallel to control for unspeciﬁc interaction with the tag and for binding and elution
dynamics. For the pull-down of speciﬁc interaction partners, a pig liver cytosol fraction,
the corresponding liver membrane fraction and, in order to study cooperative binding, a
one to one mixture of liver membranes and cytosol was used as protein source. The elu-
ates of the columns were separated by SDS-PAGE, stained with Coomassie (ﬁgure 4.30b)
and bands speciﬁcally appearing in the eluates of the DGAT2 containing column were an-
alyzed by MALDI-TOF mass spectrometry (ﬁgure 4.30c, supplementary ﬁgure A.17 and
supplementary table B.4).
Besides ATP-synthases and actin, the main liver metabolic enzymes like aldehyde dehy-
drogenase and epoxide hydrolase were identiﬁed. These proteins most probably represent
unspeciﬁcally bound proteins that were detected because of their high abundance. An ex-
ception is ACSL1 (Long Chain Acyl-CoA Synthetase 1), which could be identiﬁed in the
membrane fraction and the mixed fraction (ﬁgure 4.30, supplementary ﬁgure A.17 and sup-
plementary table B.4). ACSL1 activates fatty acids by coupling them to CoA. These FAs
can be used for oxidation in order to obtain energy or to build up storage lipids or phospho-
lipids. ACSL1 was reported to localize to the ER, to mitochondria-associated membranes
(MAM) [81] and to the cytosol [71] in hepatocytes and to mitochondria, PM and LDs in
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(a) Construct used as bait for identiﬁcation of DGAT2 interaction partner
(b) Coomassie gel of the eluates
obtained from the columns used for
the study of speciﬁc and coopera-
tive binding to DGAT2
(c) List of potential interaction partner of DGAT2
Figure 4.30.: Identiﬁcation of ACSL1 as interaction partner of DGAT2
(a) The conserved N-terminus of human DGAT2 was cloned in front of a tag consisting of a TEV protease cleavage site
(TEV), a triple hemagglutinin-tag (3HA-Tag), a Prescission protease cleavage site (Prescission) and a streptavidin
binding protein-tag (SBP-Tag). The cleavage sites allow the removal of parts or the whole tag, the HA-tag allows
localization studies with tag-speciﬁc antibodies and the SBP-tag allows speciﬁc binding of the expressed construct to
streptavidin. Restriction enzymes used for construction of the construct are labeled above, the position and length
of the elements of the construct are labeled in base pairs below.
(b) The coomassie gel shows the proteins accumulating in the eluates of the columns used to isolate speciﬁc interaction
partner of DGAT2. In lane 1 the proteins in the eluate of the column loaded with lysates of bacteria transfected
with an empty vector (control for unspeciﬁc binding to column material), in lane 2 the eluate of the column loaded
with the lysates of bacteria expressing the N-terminus hDGAT2 construct described in (a) and in lane 3 the eluate
of the column loaded with the lysates of bacteria expressing the EGFP control construct (EGFP cloned in front of
the tag described in (a) as control for unspeciﬁc binding to the tag) are shown. Bands labeled with numbers only
appeared in lane 2 and were cut out and analyzed by mass spectrometry. Only results for the columns incubated
with a mixture of cytosolic and membrane liver proteins for competitive binding are shown. For complete results see
supplementary ﬁgure A.17.
(c) In the table the proteins identiﬁed by mass spectrometry in the bands cut from the coomassie gel shown in (b)
are listed. The numbering of the hits corresponds to the numbering of the bands in (b). For the complete hit list
see supplementary table B.4. The mass spectrometric analysis and the table is provided by Cornelia Czupalla.
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3T3-L1 adipocytes [9, 82, 83]. In 3T3-L1 cells, ACSL1 interacts with the FATP1 protein and
promotes fatty acid import in a process called vectorial acylation [83, 87] or it is involved
in reesteriﬁcation of fatty acids released by lipolysis [88]. In hepatocytes, it is reported to
be involved in the synthesis of phospholipids, DAG and TAG [81, 85, 86]. As DGAT2 and
ACSL1 are both involved in anabolic lipid metabolism, an interaction might be physiologi-
cally beneﬁcial.
4.4.1.2. DGAT2 and ACSL1 partially localize to the same compartments
DGAT2 localizes to the ER compartment [28, 101], to MAM [101] and to the surface of
LDs (see section 4.1). In comparison, ACSL1 was reported to localize to the PM, the
cytosol, the ER compartment, MAM and mitochondria. The localization of these proteins
to the same compartments supports the possibility of a speciﬁc interaction. Within COS7
cells localization by immunoﬂuorescence of both proteins showed that the major portion of
DGAT2 resides in the ER or accumulates on LDs upon oleate feeding, whereas ACSL1-HA
strongly accumulates in the mitochondria, though also a staining of the ER compartment and
the cytosol is visible (ﬁgure 4.31 and supplementary ﬁgures A.18 and A.19). The localization
of DGAT2 or ACSL1-HA was not inﬂuenced by the coexpression of both proteins. To further
analyze the localization of both proteins lysates of COS7 cells overexpressing human wildtype
DGAT2 and human C-terminal HA-tagged ACSL1 were fractionated by centrifugation in a
stepwise sucrose density gradient. The fractions were analyzed for the abundance of DGAT2
and ACSL1-HA by western blotting and compared to markers for ER, mitochondria and
LDs (ﬁgure 4.32). ACSL1-HA strongly accumulates in the fractions 14 to 16 and three to
seven and colocalizes with the markers for ER (fraction three to 18), LDs (fraction one to
six) and mitochondria (fraction 14 to 16). DGAT2 accumulates mainly in fraction four and
ﬁve, where it colocalizes with the ER marker and the LD marker. Furthermore, some signal
can be detected in fraction 15 and 16, where it colocalizes with the ER and the mitochondria
marker. About 19% of the total ACSL1-HA colocalizes with 62% of total DGAT2 in the
LD or light ER fractions that represent most likely smooth ER. A minor amount of DGAT2
colocalizes with the heavy ER and mitochondria, presumably representing a localization to
MAM. In conclusion, DGAT2 and ACSL1 might interact in the ER compartment, at MAM
and at LDs.
4.4.1.3. Validation of the interaction between DGAT2 and ACSL1
For the identiﬁcation of ACSL1 as an interaction partner of DGAT2 (see section 4.4.1.1),
only the N-terminus of DGAT2 was used as bait and pig liver proteins as prey. Though
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Figure 4.31.: Cellular localization of DGAT2 and ACSL1
COS7 cells were transfected with empty vector (control), human C-terminal HA-tagged ACSL1 (ACSL1-HA), wild-
type human DGAT2 (DGAT2) or wildtype human DGAT2 and human C-terminal HA-tagged ACSL1 (ACSL1-HA
+ DGAT2) for 24 h. Cells were grown in DMEM medium supplemented with FCS. Cells were analyzed by immuno-
ﬂuorescence for lipid droplets (green), ACSL1 (blue) and DGAT2 (red). Scalebar = 10 휇m. For immunoﬂuorescence
data for delipidated FCS or FCS and 100 휇M oleate conditions see supplementary ﬁgure A.18 and A.19.
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Figure 4.32.: DGAT2 and ACSL1 partially localize to the same compartments
COS7 cells were grown in DMEM medium supplemented with normal FCS and transfected with wildtype human
DGAT2 and human C-terminal HA-tagged ACSL1 for 24 h. Cell lysates were ﬂoated in a stepwise sucrose density
gradient ranging from 15 to 70% sucrose and fractions were analyzed by SDS-PAGE/western blot. The abundance
of ACSL1 (HA-tag) and DGAT2 (DGAT2) in the diﬀerent fractions was compared to the localization of marker
proteins for ER (Calnexin), mitochondria (COX IV) and LD (TIP 47). The red and turquoise square mark the main
fractions, where both, DGAT2 and ACSL1, are detected. The coloured labeling indicates the amount of DGAT2
(turquoise) or ACSL1 (red) protein in the marked fractions related to the total protein detected in the gradient.
controls for unspeciﬁc binding to the column material and to the tag were included in
the experiment, the interaction could still be unspeciﬁc or not transferable to living cell
systems and other species. Therefore, full-length human wildtype DGAT2 and human C-
terminal HA-tagged ACSL1 were expressed either each alone or together in COS7 cells
and coimmunoprecipitated with the DGAT2 antibody or the HA antibody (ﬁgure 4.33). It
was possible to coimmunoprecipitate DGAT2 with ACSL1 and vice versa in cells overex-
pressing both proteins, but no signal for the coimmunoprecipitated protein was detected in
SDS-PAGE/western blot for single expression, showing that the signal obtained in coim-
munoprecipitation was speciﬁc. A quantiﬁcation of the amount of DGAT2 or ACSL1-HA
that was recovered by coimmunoprecipitation from total expressed DGAT2 or ACSL1-HA
revealed that 25% of total ACSL1-HA coimmunoprecipitated when DGAT2 was used as bait
and 9% of total DGAT2 was coimmunoprecipitated when ACSL1-HA was used as bait.
A comparison with the amounts of DGAT2 and ACSL1-HA protein that localize to the same
compartment (see ﬁgure 4.32) suggests that all DGAT2 comes from a compartment where
it can colocalize with ACSL1-HA. Furthermore, nearly all ACSL1-HA that colocalizes with
DGAT2 at the smooth ER (19%) and additional some ACSL1-HA at the MAM compartment
seems to be recovered by coimmunoprecipitation with DGAT2 (25% ACSL1). In contrast
to DGAT2, only about 50% of the ACSL1-HA protein immunoprecipitated comes from a
compartment, where DGAT2 and ACSL1-HA colocalize. Additionally, although they may
colocalize on MAM, ACSL1-HA seems to be much more abundant than DGAT2, therefore
the chance to immunoprecipitate an ACSL1-HA molecule that has a DGAT2 molecule bound
instead of an unbound ACSL1-HA molecule is much lower. Taken together, this explains
why only 9% of DGAT2 protein was recovered by immunoprecipitation of ACSL1-HA. In
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(a) IP with DGAT2 antibody
detection with HA antibody
(b) IP with HA antibody
detection with DGAT2 antibody
Figure 4.33.: DGAT2 interacts with ACSL1 in COS7 cells
COS7 cells were grown in DMEM medium supplemented with normal FCS and transfected with wildtype human
DGAT2 (DGAT2), wildtype human DGAT2 and human C-terminal HA-tagged ACSL1 (DGAT2 + ACSL1-HA) or
human C-terminal HA-tagged ACSL1 (ACSL1-HA) for 24 h.
(a) Cell lysates were used for immunoprecipitation with DGAT2 antibody (IP DGAT2). Coimmunoprecipitated
proteins were analyzed by SDS-PAGE/western blot with the HA-tag antibody (HA-tag AB). The upper ﬁrst two
horizontal lanes show the amount of DGAT2 (DGAT2 AB) or ACSL1-HA (HA-tag AB) in the cell lysates used for
the immunoprecipitation of DGAT2 (IP DGAT2).
(b) Cell lysates were used for immunoprecipitation with HA-tag antibody (IP HA-tag). Coimmunoprecipitated
proteins were analyzed by SDS-PAGE/western blot with the DGAT2 antibody (DGAT2 AB). The upper ﬁrst two
horizontal lanes show the amount of DGAT2 (DGAT2 AB) or ACSL1-HA (HA-tag AB) in the cell lysates used for
the immunoprecipitation of ACSL1-HA (IP HA-tag).
The coloured labeling indicates the amount of ACSL1-HA (red) or DGAT2 (turquoise) protein related to the total
protein used that is coimmunoprecipitated with DGAT2 and ACSL1, respectively.
summary, all ACSL1-HA protein of the smooth ER fraction seems to interact with DGAT2
and additionally, all DGAT2 in the MAM fraction seems to interact with ACSL1-HA.
The coimmunoprecipitation of DGAT2 and ACSL1 showed that both proteins can speciﬁ-
cally interact with each other. Nevertheless, it might be an artefact of overexpression or the
interaction could be less frequent and of minor importance. The amount of DGAT2 per cell
is very low, so that it can not be visualized by detection with our antibody. Additionally, no
antibody for the detection of untagged wildtype ACSL1 protein was available. Therefore,
DGAT2 was immunoprecipitated from wildtype COS7 cells and the coimmunoprecipitated
ACSL proteins were detected by their enzymatic activity. The use of radioactively labeled
substrates enabled to detect even minor amounts of ACSL activity. The experiments reveal
that DGAT2 interacts speciﬁcally with an ACSL activity in wildtype COS7 cells, which
most likely represents ACSL1 activity (ﬁgure 4.34).
4.4.2. Physiological role of the DGAT2-ACSL1 interaction
DGAT2 and ACSL1 both participate in lipid metabolism and they interact under physio-
logical conditions (see section 4.4.1.3). As ACSL1 catalyzes the formation of acyl-CoAs,
which are substrates for DGAT2, an interaction might speed up the formation of TAG by
54
4.4. Regulation of DGAT2 localization and activity
Figure 4.34.: DGAT2 associates with an ACSL activity in COS7 cells
COS7 cells were grown in DMEM medium supplemented with normal FCS. Cell lysates from untreated COS7 cells
(wt) or COS7 cells transfected with wildtype human DGAT2 and human C-terminal HA-tagged ACSL1 (AD) for 24
h were used for a modiﬁed immunoprecipitation of DGAT2 (DGAT2 AB). Precipitates were subjected to an ACSL
activity assay and the amount of the synthesized product [3H]acyl-CoA was measured by scintillation counting. As
control for unspeciﬁc binding, empty beads (control) were used in parallel in the immunoprecipitation procedure and
ACSL assay. The results from ten experiments are shown as box blots. The box describes the range of values that
contains half of the values measured. The crosses describe the maximum and minimum values measured and the
square represents the mean of all experiments. Signiﬁcances were calculated by unpaired two-sided t-test; * p≤0.05.
vectorial acylation. This process of substrate channeling was described in 3T3-L1 adipocytes,
where FATP1, a fatty acid transporter, and ACSL1 interact at the PM. There, ACSL1 activ-
ity is necessary for the activity of FATP1 by directly activating and metabolizing incoming
fatty acids [83, 87]. Therefore, COS7 cells overexpressing an empty vector, C-terminal
HA-tagged ACSL1, wildtype DGAT2 or both proteins were fed with [3H]oleate for 6 h or
24 h under normal growth conditions or supplemented with 100 휇M oleate. Lipids were
extracted, separated by TLC and quantiﬁed with ImageGauge. Though overexpression of
DGAT2 increases TAG synthesis, the results show that coexpression of ACSL1 and DGAT2
has no further eﬀect on de novo TAG synthesis compared to DGAT2 overexpression alone
(supplementary ﬁgure A.20). In rat primary hepatocytes [81], overexpression of ACSL1 led
to a channeling of FAs towards DAG and phospholipids and an increase in reacylation of
hydrolyzed FAs into TAG. In order to investigate whether ACSL1 has a similar role in kid-
ney ﬁbroblasts, COS7 cells overexpressing an empty vector, C-terminal HA-tagged ACSL1,
wildtype DGAT2 or both proteins were fed with [14C]acetate for 6 h under normal growth
conditions. Lipids were extracted, separated by TLC and quantiﬁed with ImageGauge. Nei-
ther single ACSL1 expression nor coexpression with DGAT2 revealed changes in the ﬂux
of fatty acids to certain lipids (supplementary ﬁgure A.21). If ACSL1 and DGAT2 interac-
tion has no eﬀect on acceleration or channeling in lipid metabolism, it might be beneﬁcial
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for the stability of DGAT2 and thus control the duration of DGAT2 activity. Labeling of
DGAT2 with [35S]methionine and quantiﬁcation of labeled DGAT2 protein after diﬀerent
chase times revealed a half time of about three hours under normal growth conditions. The
half time of DGAT2 was not inﬂuenced by the coexpression of ACSL1 (supplementary ﬁgure
A.22).
Though the interaction of ACSL1 and DGAT2 does not inﬂuence the direct speed of lipid
metabolism, the lipid species synthesized or the stability of DGAT2, it seems to have an
inﬂuence on the packaging of the synthesized lipids in LDs. The immunoﬂuorescence data
on the morphology of LDs in COS7 cells overexpressing an empty vector, C-terminal HA-
tagged ACSL1, wildtype DGAT2 or both proteins (ﬁgure 4.31) indicate an increase in LD
number upon overexpression of DGAT2 and a slight enlargement in LD size upon ACSL1
overexpression. The analysis of diﬀerent immunoﬂuorescence pictures from several experi-
ments with Image J displays signiﬁcant diﬀerences in the number and size of LDs. DGAT2
expression leads to more but smaller LDs, whereas ACSL1 expression shifts the mean droplet
size towards larger droplets (ﬁgure 4.35). Overexpression of both proteins leads to a similar
size distribution of the droplets, but a higher number. Diﬀerences were most prominent
under delipidated conditions.
In order to conﬁrm these size diﬀerences, LDs from COS7 cells grown in DMEM with
10% FCS and overexpressing an empty vector, C-terminal HA-tagged ACSL1, wildtype
DGAT2 or both proteins were isolated by modiﬁed sucrose density gradient centrifugation
and analyzed by electron microscopy. The LD diameter was analyzed manually on several
pictures from three independent experiments (see ﬁgure 4.36). The measurements reveal a
mean LD diameter of 105 nm for control cells. The mean LD diameter decreases signiﬁcantly
in DGAT2 overexpressing cells (40 nm, p=2.79427E-12) and increases signiﬁcantly in ACSL1
overexpressing cells (267 nm, p=9.05731E-19). The expression of both proteins induced a
slightly enlarged mean LD diameter compared to control cells (171 nm, p=3.72301E-07).
All measured LDs from the EM pictures from three experiments are displayed as LD size
distributions in ﬁgure 4.37. The size distribution reveals that more small LDs were measured
upon DGAT2 overexpression and more large LDs were measured upon ACSL1 overexpression
compared to control cells. Though the expression of both proteins ends up in a mean LD
diameter similar to control, the distributions reveal that more small and more large LDs are
measured upon coexpression of DGAT2 and ACSL1 than in the control. The distribution
obtained for coexpression of DGAT2 and ACSL1 most likely represents the addition of both
individual phenotypes.
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(a) Changes in the number of LDs (b) Changes in the size of LDs
Figure 4.35.: The ratio between DGAT2 and ACSL1 inﬂuences the packaging of stored TAG
COS7 cells were transfected with empty vector (Control), human C-terminal HA-tagged ACSL1 (ACSL1), wildtype
human DGAT2 (DGAT2) or wildtype human DGAT2 and human C-terminal HA-tagged ACSL1 (ACSL1 + DGAT2)
for 24 h. Cells were grown in DMEM medium supplemented with delipidated FCS (DL), normal FCS (FCS) or FCS
and 100 휇M oleate (oleate). Cells were analyzed by immunoﬂuorescence (see ﬁgure 4.31) and several images from
three diﬀerent experiments were analyzed with Image J. The mean number of LDs (a) and the mean LD diameter
(b) for all four expressed constructs and for all three conditions are shown. Signiﬁcances were calculated by unpaired
two-sided t-test relative to control; * p≤0.05; ** p≤0.01.
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Figure 4.36.: ACSL1 and DGAT2 inﬂuence the size of LDs
COS7 cells grown in DMEM with 10% FCS and overexpressing an empty vector (Control), C-terminal HA-tagged
ACSL1 (ACSL1), wildtype DGAT2 (DGAT2) or both proteins (ACSL1 + DGAT2) were isolated by modiﬁed sucrose
density gradient centrifugation and analyzed by electron microscopy. Representative images are shown; scalebar =
1 휇m. Images were acquired by Kevin Manygoats and Daniela Vorkel.
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(a) Control (b) DGAT2
(c) ACSL1 (d) ACSL1 + DGAT2
(e)
Figure 4.37.: The ratio between DGAT2 and ACSL1 inﬂuences the size distribution of LDs
COS7 cells grown in DMEM with 10% FCS and overexpressing an empty vector (Control), C-terminal HA-tagged
ACSL1 (ACSL1), wildtype DGAT2 (DGAT2) or both proteins (ACSL1 + DGAT2) were isolated by modiﬁed sucrose
density gradient centrifugation and analyzed by electron microscopy. The diameter of the isolated LDs was measured
manually from several electron microcopy pictures obtained for each condition (see ﬁgure 4.36). The size distribution
of LDs for Control is diplayed in (a), for DGAT2 in (b), for ACSL1 in (c) and for ACSL1 + DGAT2 in (d). All four
size distributions are summarized in (e); Control (red), DGAT2 (blue), ACSL1 (yellow), ACSL1 + DGAT2 (green).
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5. Discussion
The results obtained in chapter 4 are discussed with respect to methodological aspects and
they are compared with the observations of others. Additionally, they are set into broader
context regarding their physiological signiﬁcance and their involvement in diverse metabolic
processes and disorders.
5.1. LDs grow by local synthesis of TAG and PC
The growth of LDs requires expansion of volume and surface area. LDs can gain additional
lipids by diﬀerent mechanisms, which are probably not exclusive and might promote each
other. Four mechanisms are possible, which might be used depending on the need and cell
type: LDs can grow (i) by homotypic fusion of LDs, (ii) by facilitated monomeric diﬀusion
of lipids, (iii) by localized synthesis at the LD surface or (iv) by transport via continuities of
the LD monolayer with the ER membrane. The growth of LDs and the incorporation of FAs
into TAG is a fast event, typically taking just a few minutes [28, 171]. Homotypic fusion was
recently observed in NIH-3T3 ﬁbroblasts [130, 131]. Since it was not reported by others,
who investigated LD growth, it seems to be a rather rare event that is unlikely to account
for the rapid biosynthetic transport of droplet constituents [25, 28]. Additionally, recent
data negate the formation of new small LDs and fusion to bigger LDs upon FA supply, but
rather show the growth of already existing LDs supposably by local synthesis of TAG [171].
Transporters for FAs and PC binding proteins have been reported [65, 69, 119], but their
role remains unclear and no similar proteins were discovered for TAG so far. It has been
shown that membrane continuities can exist [13, 120, 121], but it is uncertain whether they
occur frequently or rather represent a rare intermediate state of LD biogenesis.
The data presented in section 4.1 show that TAG synthesis as well as PC synthesis can
occur on LDs, which enables them to grow by local synthesis. The origin of the long-chain
acyl-CoA species that are used by LPCAT1, LPCAT2 and DGAT2 is likely local production
by ACSL3, an abundant constituent of LDs [76, 77] or by ACSL1, which can interact with
DGAT2 (section 4.4.1) and was found in the vicinity of LDs and in adipocytes even on
LDs [9]. The other precursor of TAG, DAG, could be produced at the ER by phosphatidic
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acid phosphatase or derives from lipolysis of TAG. As shown in section 4.1.1.2, LDs contain
suﬃcient DAG to produce measurable amounts of TAG [28]. For the other precursor of
PC, LPC, the most likely source is production by action of PLA2 either at the LD [14]
or on other membrane compartments, probably the ER, followed by transport to the LD.
Potential candidates for the PLA2 activity are iPLA2, the key activity in the Lands cycle
of membrane lipid remodeling and involved in stress response of LDs [172] or cPLA2, an
important player in LD biogenesis [173]. Another possibility is the recently discovered
adipocyte-speciﬁc PLA2 [174], whose genetic ablation in mice results in strongly reduced
TAG storage [175]. LPC is spontaneously released from membranes with a half-time of 13-20
milliseconds [176]. Desorption from membranes and transport in the cytosol are supported
by binding to fatty acid binding proteins (FABPs) [65]. It should be noticed that the same
principle, i.e. monomeric transport of a lyso-phospholipid followed by vectorial acylation
at the target membrane, is used for the synthesis of PA. LPA is produced in mitochondria,
transported to the ER by FABP [177] and converted to PA by an ER-resident LPAAT
activity [150].
Local synthesis of TAG and PC has several advantages over the other mechanisms. In case
of diﬀusion via membrane continuities, the surface lipid composition of LDs should resemble
that of the ER. This would make it diﬃcult to distinguish LDs and ER as separate targets
for example for transport, signaling or metabolic activities. Additionally, it would not be
possible to enrich the LD in certain lipids, if free diﬀusion existed between ER and LD. It
was shown that the LD surface has a diﬀerent lipid composition than the ER [8]. The local
activity of LPCAT1 and LPCAT2 provide a unique LD surface lipid proﬁle and enables to
speciﬁcally enrich the LD in certain lipids (see section 4.2.1). Thus, local synthesis provides
speciﬁcity and directionality to lipid synthesis. Fusion of LDs requires a change in LD surface
lipids or protein composition to modulate surface tension and curvature to promote fusion
[178, 179]. Furthermore, this growth mechanism requires the synthesis of new LDs prior
to delivery to already existing LDs, which does not seem to be the case in 3Y1 ﬁbroblasts
or 3T3-L1 adipocytes [171]. Fusion between old and new LDs might be problematic, as it
was reported that the protein composition changes during LD growth [25]. Though lipid
binding and transfer proteins exist, they are often not speciﬁc for a certain lipid and a
certain transport route [119]. For transport as well as fusion it might be diﬃcult to regulate
the magnitude and the directionality of the reaction, especially, as already existing LDs
are not loaded equally with newly synthesized lipids [28, 171]. Therefore, local synthesis
of the major LD lipids, TAG and PC, allows the independent and precise regulation of LD
loading. Additionally, it enables the LD to rapidly respond to nutritional changes or to
adapt its size.
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The local activity of DGAT2, LPCAT1 and LPCAT2 might be important to maintain a low
level of toxic lipid intermediates, such as FFAs or LPC. Upon supply with exogenous FAs
DGAT2 localizes to LDs and imported FAs can be rapidly incorporated into diﬀerent lipids
[28]. In this process not only TAG is formed and stored in LDs, but already measurable
amounts of DAG accumulate in LDs. The DAG pool may therefore act as a reservoir to
support the import of FAs while keeping the cellular pool of FFAs low [63, 64]. At later
timepoints the DAG can be converted to phospholipids and to the long-term storage form
TAG by the DGATs or FAs can be released for 훽-oxidation. The local synthesis of TAG
at LDs makes additional transporters for transport of DAG to the ER and TAG back to
the LD unnecessary, thereby accelerating lipid metabolism. FFAs and LPC are known
to disrupt membranes and to function in cell death [180]. In order to prevent unwanted
accumulations they can be incorporated into PC molecules. As LDs can store LPC [8], are
usually disconnected from membranes and are able to synthesize PC, they are good locations
for the detoxiﬁcation of LPC and FFAs.
The activity of DGAT2, LPCAT1 and LPCAT2 might also be involved in the regulation
of fusion between LDs and in LD budding from the ER during LD biogenesis. As LPC
and DAG change the curvature of membranes and modulate fusion [178, 179], regulation
of local DGAT and LPCAT activity of LDs might be crucial for the regulation of budding
or fusion events. Furthermore, as the activities of LPCAT1, LPCAT2 and DGAT2 seem
to determine the lipid composition of the LD, their regulation might be involved in the
speciﬁc recruitment of certain proteins. Supporting this hypothesis, LDs in adipocytes are
reported to change protein composition during maturation [25] or upon lipolytic stimulation
[9]. Recently, it was shown that the accumulation of DAG in a membrane promotes the
recruitment of TIP47, S3-12 and OXPAT to this membrane [181], which suggests a link
between lipid composition and protein composition that might be favorable to adapt lipid
metabolism to the cellular metabolic state.
5.2.1. Size regulation of LDs
Regarding the growth of LDs, two LD components have to increase in size: the LD core,
mainly consisting of neutral lipids, and the LD surface, mainly consisting of PC. The LD
grows upon synthesis of TAG, either by DGAT1 [93] or by DGAT2 [95], but only DGAT2 can
localize to LDs and was reported to be crucial for TAG synthesis. Concerning the growth of
LDs the LD surface layer has to expand with similar kinetics as the LD volume, otherwise
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the surface-to-volume ratio will change. This requires a coordination between TAG and PC
synthesis. The inhibition of PC synthesis reduces the amount of available LD surface. This
leads to a change of the surface-to-volume ratio by concomitant unchanged or increased
amounts of TAG and it results in the formation of larger LDs.
Interestingly, both, the inhibition of de novo PC synthesis and the inhibition of the membrane-
remodeling pathway, result in the formation of larger LDs, but this is achieved by diﬀerent
mechanisms. Inhibition of the de novo pathway shifts FAs determined for PC production
towards the production of TAG (supplementary ﬁgure A.7, [151]). In this case LDs enlarge,
because the growth of their volume exceeds the growth of their surface. In contrast, inhibi-
tion of the membrane-remodeling pathway does not change the amount of neutral lipids, but
restricts only the amount of available LD surface material. This leads to a reorganisation
of the LD pool, which results in the formation of larger LDs (see section 4.2.2) in order to
reduce the surface-to-volume ratio.
The magnitude, with which the diﬀerent LPCATs participate in LD surface formation, has
still to be dissected. LPCAT1 and LPCAT2 localize to the LD surface and to the ER and a
knock-down does not provide information, whether both enzyme pools participate equally
in the LD surface formation. Additionally, the role of LPCAT3 activity in this process is
still unclear. Though in vitro studies revealed a preference for FAs that are rare at the
analyzed LDs [110, 111, 117], a recent study reported similar FA preferences for LPCAT3 as
for LPCAT1 and LPCAT2 in vivo [118]. Nevertheless, it might be possible that the acquired
proﬁle after LPCAT3 knock-down or overexpression results from concomitant changes in the
activities of LPCAT1 and LPCAT2 rather than from direct eﬀects of LPCAT3 decrease.
Besides direct modulation of the LD surface and indirect modulation of the LD volume by
shifts in the FA metabolism, the LD size can be inﬂuenced by direct changes of the LD
volume. Activation of DGAT results in enhanced formation of TAG [90], which is stored
in LDs. This does not necessarily result in bigger LDs. Instead, overexpression of DGAT2
leads to the formation of more, but smaller LDs (see 4.4.2). This suggests that enhanced
presence and activation of DGAT2 could upregulate the quantity or activity of LD surface
forming enzymes. In conclusion, LD size regulation seems to depend on the interplay of
diﬀerent enzymes, in particular their abundance and activity.
5.2.2. LD size inﬂuences the lipid metabolism
Lipogenesis and lipolysis are multi-step processes that require the action of diﬀerent enzymes
(see chapter 2). Several of these enzymes attach directly to the surface of LDs. Therefore,
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the size of LDs and the availability of surface is one determining factor for the availability
of substrates for these enzymes. If more surface is available, more enzymes can bind to the
LD and faster synthesis or degradation of lipids can occur. This suggestion is supported
by the ﬁnding that LD fragmentation seems to be connected to lipolysis [3, 9]. Though
fragmentation is not necessary for lipolysis, the ﬁnding that fragmentation of LDs promotes
lipolysis [55, 56] further supports the importance of LD size for the lipid metabolism.
Changes in the cellular lipid metabolism can shift the cellular balance between lipid stor-
age, lipid oxidation, lipid release, lipid uptake and lipid-carbohydrate metabolism. It was
reported that a decrease in DGAT2 leads to a reduction in lipoprotein particle secretion
[182], but this reduction is mainly due to reduced amounts of TAG available in the cells.
Recently, a more surprising regulation of lipoprotein particle secretion was reported. It was
shown that a decrease in ACSL3 protein results in a secretion defect for VLDL particles from
hepatic cells [77]. The defect was mainly due to reduced availability of PC. In this thesis,
a similar phenotype was observed upon reduction of LPCAT1 protein levels in hepatic cells
(see section 4.2.3). Similar to LPCAT3 reduction, reduction in LPCAT1 results in decreased
LPCAT activity and therefore also decreased availability of PC. This reduction leads to a
decreased release of apoB, of radioactively labeled lipids, and of with lipoprotein particles
associated hepatitis C virus particles.
The reduction in apoB secretion from HuH7 cells upon LPCAT1 knock-down seems to
result from a simple decrease in lipoprotein particle secretion and not from a modiﬁcation
of the lipoprotein particles. The reduction of LPCAT1 leads to only minor changes in the
composition of secreted lipids (see supplementary ﬁgure A.13), but reduces the amount
of secreted lipids signiﬁcantly. Decreased release of lipoprotein particles is supported by a
decreased release of HCV particles. HCV particles are reported to depend on VLDL secretion
for their release from hepatic cells [154]. The phenotype was only detected with one of the
two LPCAT1 targeting siRNAs, which might depend on the less eﬃcient reduction of the
LPCAT1 protein with the other sequence and the need of a certain threshold to inﬂuence
virus particle release. Diﬀerences in the strength of the reduction phenotype (apoB analyzed
by western blot or ELISA, lipid secretion and HCV release) most likely result from diﬀerences
in the methods and incubation times.
Interestingly, though large amounts of PC are available in the ER, the assembly locus for
lipoprotein particles, the secretion is inﬂuenced by the modiﬁcation of a small PC pool within
the cells. Taking into account the inﬂuence of PC availability on lipolysis, it is suggested
that the availability of PC modulates the lipoprotein particle secretion eﬃciency by slowing
down the release of lipids from LDs by lipolysis. These lipids are required for lipoprotein
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Figure 5.1.: A model to integrate triglyceride and phospholipid metabolism
The cellular homeostasis of PC is a complex process, in which PC biosynthesis via the Kennedy pathway (No.1)
and PC turnover by the Lands cycle (No.2) are key elements. The Lands cycle consists of degradation by PLA2
and re-acylation by LPCAT. Re-acylation does not take place exclusively in the ER (LPCAT1-3), but also on the
LD surface (LPCAT1+2, No.3). Reduced PC biosynthesis via the Kennedy pathway results in increased production
of TAG, likely a compensatory mechanism to deposit the excess FAs that are not used for membrane expansion.
The speciﬁc reduction of PC biosynthesis on LDs by knock-down of LPCAT1 and/or LPCAT2 results in an increase
of LD size, which can be explained by an imbalance of the synthesis of LD surface PC relative to LD volume.
Likewise, TAG biosynthesis is compartmentalized in the same way between ER (DGAT1 and DGAT2, No.4) and
LDs (DGAT2, No.6), where DGAT2 concentrates in response to excess fatty acids (No.5). DGAT2 and LPCAT1
are both important for normal secretion of lipoprotein particles, which are assembled in the ER by microsomal
triglyceride transfer protein (MTP, No.7). This demonstrates a close connection between synthesis of LD surface,
LD volume and secreted lipoproteins.
particle assembly (summarized in ﬁgure 5.1). In conclusion, the results show that already
small changes like the diﬀerent packaging of TAG can have severe consequences beyond
the cell level. As the development of many diseases is connected to the lipid level in the
circulation and the hepatitis C virus release relies on the secretion of lipoprotein particles
[154], it will be of interest to study these ﬁndings in more detail.
5.3. Formation and regulation of subcellular lipid pools
In lipid metabolism most reactions are catalyzed by enzyme families. Usually several iso-
enzymes that catalyze the same reactions, belong to these families, but they diﬀer in struc-
ture and subcellular localization [64, 111]. This allows compartmentalization of synthesis
and maintenance of separate pools with diﬀerent fates. But as these iso-enzymes are often
unable to substitute for each other, it makes cells susceptible for defects in one of the en-
zymes. This explains why the activity of LD-associated LPCAT1 is important for secretion
of lipoprotein particles in HuH7 cells, although the cell contains abundant ER-associated
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LPCAT activity provided by LPCAT3 [110]. The compartmentalization of the PC biosyn-
thesis between ER and LD parallels the TAG biosynthesis. In order to obtain a separation of
iso-enzymes, they must contain recognition motifs or structures. These motifs would enable
the cell to target certain iso-enzymes to the LD (DGAT2, LPCAT1 and LPCAT2), while
others remain in the ER (DGAT1, LPCAT3 and LPCAT4).
Concerning the DGAT iso-enzymes, DGAT1 is a polytopic transmembrane protein localizing
to the ER [91], while DGAT2 is a monotopic protein (see section 4.3.2, [92]) with localization
to both ER and LDs (see section 4.1.1, [28], [101]). Likewise, the biosynthesis of PC via
acylation of LPC can either take place at the ER by the action of the polytopic enzymes
LPCAT3 and LPCAT4 [111], which actually belong to the same protein family as DGAT1,
or at the LDs by the activity of the monotopic proteins LPCAT1 and LPCAT2 (see section
4.3.1). The principle behind is the same: the diﬀerent physical properties of bilayer and
monolayer membranes lead to separation of iso-enzymes with polytopic and monotopic mode
of membranes insertion.
5.3.1. Interaction of DGAT2 and ACSL1
The importance of the subcellular localization and the ratio of the amounts of enzymes
in lipid metabolism is demonstrated by the interaction of DGAT2 and ACSL1. While
ACSL1 shows broad distribution in various membranes and organelles, DGAT2 seems to
be restricted to certain regions in the ER and the LDs (see ﬁgure 4.31 and 4.32). ACSL1
and DGAT2 speciﬁcally interact with each other (see section 4.4.1.3). The interaction is
likely mediated via one of two potential sequence motifs revealed by bioinformatical analysis
(see ﬁgure 4.29). Concerning the conservation of these motifs in diﬀerent species, the motif
at amino acid position 62 to 73 is highly conserved and therefore more likely to account
for the speciﬁc interaction. Interestingly, this motif was found to be involved in targeting
of DGAT2 to mitochondria-associated membranes (MAM) [101]. As a signiﬁcant amount
of ACSL1-HA is suggested to localize to MAM (see ﬁgure 4.31 and 4.32), but the amount
of DGAT2 in this location is low, it is possible that ACSL1 traps DGAT2 at MAM via
speciﬁc binding. This is supported by the ﬁnding that a disruption of the putative ACSL1-
DGAT2 binding site reduced DGAT2 association to MAM drastically [101]. Whether the
localization of DGAT2 to MAM is accidental, as it get trapped by ACSL1, which is abundant
in this compartment, or whether it represents a physiological relevant localization needs to
be further investigated. In contrast, as most DGAT2 localizes to speciﬁc ER regions (see
ﬁgure 4.31 and 4.32) and nearly all ACSL1-HA coimmunoprecipitated seems to interact
with DGAT2 there, it is likely that the localization of ACSL1-HA into DGAT2-containing
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ER regions depends on the speciﬁc targeting of DGAT2. Via the potential binding motif
ACSL1 might be recruited to these membrane regions together with DGAT2. The functional
analysis of the potential binding motifs is currently under way and a localization study of
mutated DGAT2 and ACSL1 might answer the question, to which extent ACSL1 localization
depends on DGAT2.
The role of the interaction between DGAT2 and ACSL1 in lipid metabolism also remains
to be analyzed further. Though ACSL1 is likely involved in providing activated FAs for
the formation of TAG by DGAT2, coexpression of both proteins does not seem to inﬂuence
TAG synthesis beyond the rates obtained by overexpression of DGAT2 alone. Nevertheless,
this does not exclude a supporting eﬀect of ACSL1 on TAG synthesis by DGAT2. ACSL1
might just not be the limiting factor in this system or another regulating component is
missing. This is supported by the ﬁnding that the highly conserved sequence at the ex-
treme N-terminus of mammalian DGAT2 (see ﬁgure 4.29) does not seem to be involved
in ACSL1-DGAT2 interaction, but presumably mediates a speciﬁc interaction with other
regulating factors. Additionally, several speciﬁc mass spectrometric proﬁles were obtained
in the analysis of potential DGAT2 interaction partners, which could not be allocated to
a certain protein. This can be explained by the use of pig liver and the existence of an
only incomplete protein mass spectrometry proﬁle database for the pig proteome. Further-
more, ACSL1 does not seem to inﬂuence the cellular lipid proﬁle, though it was reported
that ACSL1 increases FA incorporation into TAG and shifts FAs into DAG and phospho-
lipids [81, 85, 86, 88]. The discrepancies might be due to the use of diﬀerent radioactively
labeled lipid precursors ([14C]acetate versus [14C]oleate), the diﬀerent transfection condi-
tions (transient vector transfection, adenovirus-based transfection for overexpression versus
knock-down or liver-speciﬁc knockout) and the use of diﬀerent cell lines (african green mon-
key kidney ﬁbroblasts, rat primary hepatoma cells, mouse 3T3-L1 adipocytes and primary
hepatocytes from liver-speciﬁc knockout mice).
Though ACSL1 shows no direct inﬂuence on lipid synthesis rates, it inﬂuences the packaging
of lipid into LDs, as it promotes the formation of larger LDs (see ﬁgure 4.35, 4.36 and
4.37). One possibility, how ACSL1 inﬂuences LD morphology, might be via the control of
DGAT2 mobility. As DGAT2 can change localization from ER to LDs upon oleate-feeding
and preliminary data from FRAP (ﬂuorescent recovery after photobleaching) experiments
suggests a high mobility of DGAT2 within the ER (data not shown), it is possible that
ACSL1 traps DGAT2 for a longer timeperiod at a certain location, which leads to the
formation of larger LDs. Overexpression of DGAT2 alone leads to the formation of many,
but small LDs. This can be explained by suggesting that DGAT2 resides at the location of
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LD formation and ﬁlls the LD with TAG. In combination with the high DGAT2 mobility,
the time that a DGAT2 molecule stays at this location and ﬁlls a LD with TAG instead
of moving and starting the formation of a new LD elsewhere is shorter than when it is
associated with ACSL1. However, the analysis of the LD size proﬁle upon coexpression
of DGAT2 and ACSL1 revealed a combination of many small and many big LDs, whereas
control cells mainly exhibit medium sized LDs. This might result from diﬀerences in the
expression of DGAT2 and ACSL1 over the whole cell population, as some cells will only
overexpress one of both enzymes or in diﬀerent ratios.
Another possibility, how ACSL1 might inﬂuence LD morphology could result from chan-
neling of FAs and control of other enzymatic activities. Though changes in FA incorpora-
tion could not be detected in this thesis, they were reported to occur by others. ACSL1
overexpression might channel FAs towards TAG and away from PC formation, which would
inﬂuence the surface-to-volume ratio of LDs and lead to enlarged LDs as discussed in section
5.2.1. Besides this indirect inﬂuence, ACSL1 might participate in the direct regulation of
other enzymes, for example LPCATs, by blocking interaction sites of the DGAT2 molecule,
by inﬂuencing its localization or by the modiﬁcation, recruitment or release of an unknown
regulator.
5.4. Impact of DGAT2, LPCAT1 and LPCAT2 on lipid metabolic
diseases
Many diseases are associated with increased levels of plasma lipids like diabetes and atherio-
sclerosis [145, 147]. Medication that targets lipid release into the blood circulation would be
beneﬁcial for these diseases. However, the reduction of lipid release leads to accumulation
of lipids within cells, which results in obesity, inﬂammation and interference with cellular
function up to cell death [144, 145, 149]. In this context, medications that block one of
the processes strongly will also strongly accelerate the pathologic development of the other
process. Therefore, the knowledge about the function and regulation of LPCAT1, LPCAT2
and DGAT2 might render them useful as targets for medication. The phenotypes of LPCAT1
and LPCAT2 knock-down are relatively modest. Thus, a light reduction in lipid release
might lower the level of plasma lipids below the pathologic threshold, but causes only minor
lipid accumulations within cells. Therefore, the use of LPCAT1 and LPCAT2 as targets can
elongate the timeframe until insulin resistance develops and for therapies like food restriction
and sports. Additionally, targeting the cellular LPCAT activity might improve inﬂammation
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in obesity, as it was reported to regulate the inﬂammatory response to microbial stimuli and
cytokine production in monocytes and epithelial cells [183].
Concerning DGAT2, it is the main DGAT in the liver and it is involved in lipid release [182].
However, mice overexpressing DGAT2 exhibit low plasma lipid level, but lipid accumulation
in the liver [184]. Interestingly, DGAT2 overexpression was not associated with insulin
resistance, but could result in the development of hepatic steatosis. Therefore, it might
be an interesting target to treat hepatic steatosis or to reduce the plasma lipid level. As
DGAT2 is crucial for survival, direct medication targeting DGAT2 itself might lead to severe
adverse eﬀects. Therefore, understanding the regulation of DGAT2 provides new targets for
treatment of metabolic diseases. Targeting for example ACSL1 might inﬂuence DGAT2,
but could exhibit reduced adverse eﬀects.
Besides metabolic disorders, medication targeting LPCAT1 and DGAT2 could improve the
treatment for hepatitis C virus infection. As hepatitis C virus release is strongly linked to
lipoprotein particle release [154] and this process is connected to the activity of LPCAT1
and DGAT2, inhibition of their activity could reduce the dispersion of the virus within the
body.
In conclusion, detailed knowledge of the function and regulation of single players in lipid
metabolism helps to understand regulations and eﬀects on the whole cellular lipid metabolism
and allows to explain and manipulate lipid mediated eﬀects on the entire organism.
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6.1. Materials
6.1.1. Cell lines, cell culture media, bacteria strains and Drosophila
melanogaster strains
The human ﬁbroblast skin cell line A431 and the african green monkey kidney ﬁbroblast cell
line COS7 were from ATCC (Virginia, US) with the ID numbers CRL-1555 and CRL-1651,
respectively. The human hepatoma cell line HuH7 was from HSRRB (Shinjuku, Japan)
with the ID number JCRB0403. Dulbeccos modiﬁed Eagles medium with high glucose
and sodium pyruvate (DMEM), Dulbeccos modiﬁed Eagles medium without pyridoxine hy-
drochloride, L-glutamine, sodium pyruvate, L-methionine and L-cysteine, Opti-MEM, RPMI
1640, fetal calf serum (FCS) and trypsin were obtained from Gibco (Karlsruhe, Germany).
Delipidated FCS was prepared by solvent extraction with diisopropylether and butanol
and dialysis against PBS. Non-essential amino acids and L-glutamine were from Invitrogen
(Karlsruhe, Germany). For cloning and expression the E.coli strains DH5훼, JM110 (dam-)
and ER2566 were used. The following Drosophila melanogaster strains were obtained from
Bloomington (Indiana, US): wildtype, OregonR (ORK); white-mutant, w1118; strain 13872,
y1 P{SUPor-P}CG32699KG05104; strain 19866, y1 w67c23 P{EPgy2}CG32699 EY07993
and strain 10101, w1118 P{EP}EP912EP912 CG32699EP912.
6.1.2. Chemicals
Thin layer chromatography (TLC) silica gel 60 plates were from Merck (Darmstadt, Ger-
many). Human apolipoprotein B ELISA푃푅푂 was from Mabtech (Nacka Strand, Sweden).
Protein detection assay was from Bio-Rad (Munich, Germany). The transfection reagent
Lipofectamine 2000 was from Invitrogen (Karlsruhe, Germany) and Interferin from BIOMOL
(Hamburg, Germany). CoenzymeA (CoA) sodium salt hydrate was from Sigma (St. Louis,
US). The dye 4’,6-Diamidino-2-phenylindol (DAPI) was from Sigma-Aldrich Chemie GmbH
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(Taufkirchen, Germany), 4,4-diﬂuoro-1,3,5,7,8-penta-methyl-4-bora-3a,4a-diaza-s-indacene
(BODIPY 493/503) was from MoBiTec and LD540 was provided by Christoph Thiele
and Johanna Spandl. Protein A sepharose (CL4B) was from GE Healthcare, streptavidin-
sepharose was from Amersham Bioscience (Uppsala, Sweden). Digitonin was from Applichem
(Darmstadt, Germany).
6.1.3. Plasmids, ESTs, DNA primer, siRNAs, enzymes
Table 6.1.: Plasmids
ESTs were obtained from RZPD (Heidelberg, Germany) with the following ID numbers:
LPCAT1-EST IMAGp998F2213627Q, LPCAT2-EST IRAUp969E0210D6 and ACSL1-EST
IRAKp961A1191Q. All primers were from Biospring (Frankfurt, Germany). All siRNA
sequences were from Ambion (Austin, Texas) with the following order IDs: siRNA1#1:
127470, siRNA1#2: 127471, siRNA1#3: 127469, siRNA2#1: 25681 and siRNA2#2: 140447.
Enzymes for cloning and calf intestine alkaline phosphatase (CIAP) were obtained from New
England Biolabs (Frankfurt, Germany), Fermentas (Mannheim, Germany) or the MPI-CBG
protein expression facility. Proteinase K was obtained from Applichem (Darmstadt, Ger-
many).
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6.1.4. Lipids and radioactive substances
16:0-LPC, 16:0-LPA and CDP-choline were from Fluka, oleoyl-CoA, palmitoyl-CoA and
dioleoyl-diacylglycerol (DODG) were from Sigma (St. Louis, US). Oleate and palmitate
were from Acros (Geel, Belgium). Synthetic lipid standards were from Avanti Polar Lipids
Inc. (Alabaster, AL), Larodan Fine Chemicals (Malmo¨, Sweden) and Sigma-Aldrich Chemie
GmbH (Munich, Germany). [14C]CDP-choline was from Biotrend (Cologne, Germany),
[3H]oleate was from Hartmann Analytic (Braunschweig, Germany). [3H]acyl-CoAs were
synthesized as described [185]. [35S]methionine was from Perkin Elmer Life Science (Rodgau,
Germany).
6.1.5. Antibodies
Primary antibodies
Table 6.2.: Primary antibodies
Secondary antibodies
The goat anti-mouse and the goat anti-rabbit antibodies coupled with the ﬂuorophore
Alexa488, Alexa555 or Alexa647 and the rabbit anti-goat antibody coupled with horseradish
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peroxidase (HRP) were obtained from Invitrogen (Karlsruhe, Germany). The goat anti-
mouse and anti-rabbit antibodies coupled with horseradish peroxidase (HRP) were obtained
from Jacksons Immunological (West Grove, PA).
6.2. Methods
6.2.1. Methods of molecular biology
6.2.1.1. Cloning
First, primer for ampliﬁcation of the desired DNA sequence by PCR were designed and
the appropriate restriction enzyme sites were added. The DNA fragment was ampliﬁed by
PCR either from an EST sequence or from an already existing construct. The PCR product
was puriﬁed with the Qiaquick PCR puriﬁcation kit and the chosen vector and the puriﬁed
product were digested with the appropriate restriction enzymes over-night. The resulting
open ends in the vector were dephosphorylated with CIAP. Then, the restricted products
were separated according to their size by agarose gel electrophoresis and the DNA fragments
of the desired size were cut out and puriﬁed with the Qiaquick gel extraction kit from Qiagen
(Hilden, Germany). The digested and puriﬁed vector and PCR products were fast ligated
(10 min at RT) and transfected into E.coli DH5훼. Successfully transfected E.coli were
selected on agar-plates supplemented with antibiotica matching the antibiotic resistance gene
of the vector. Resistant colonies were raised in small (2 ml) suspension cultures and plasmids
were isolated with the QiaPrep® Spin MiniPrep kit. All newly constructed plasmids were
veriﬁed by sequencing. Bacteria colonies with correct plasmids were grown in big cultures
(450 ml) and plasmids were isolated with the QiaPrep® Spin MaxiPrep or Nucleobond AX
kit from Macherey-Nagel (Du¨ren, Germany).
6.2.2. Methods of cell biology
6.2.2.1. Bacteria culture
E.coli strains were grown at 37°C on LB-agar-plates or in LB-medium consisting of 5 g/l yeast
extract, 10 g/l NaCl, 10 g/l tryptone and containing ampicillin (100 휇g/ml) or kanamycin
(50 휇g/ml).
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6.2.2.2. Cell culture
A431 and COS7 cells were maintained in DMEM (Gibco 31966) with 10% FCS, HuH7 cells
in RPMI (Gibco 31870) supplemented with 10 mM HEPES, 0.1 mM non-essential amino
acids, 2 mM L-glutamine and 10% FCS at 37°C and 5% CO2. If indicated, normal FCS was
replaced by delipidated FCS (DL-FCS).
6.2.2.3. Fly culture
Drosophila melanogaster strains were kept at room temperature in tubes with food. The
food source contained 8 g agar, 10 g soybean, 18 g yeast extract, 80 g maize, 22 g glucose
sirup, 80 g malt, 1.5 g nipagin in 5 ml ethanol and 6 ml propionic acid in 1 l water. Flies
were transferred to new tubes not later than two weeks.
6.2.2.4. Isolation of larval fat bodies from Drosophila melanogaster
Four to ﬁve L3 larvae of each strain were collected and dissected in PBS on ice. Fat bodies
were transferred in PBS onto an object slide on ice and covered with a coverslip. Microscopy
was performed with a 100x NA 1.3 oil objective using bright ﬁeld.
6.2.2.5. Transfection
Bacteria were either transfected by heat shock or by electroporation. For the heat shock,
DNA and bacteria were mixed on ice for about 10 min, then exposed to 42°C for 90 sec and
spread onto agar-plates for selection. For electroporation, bacteria and DNA were mixed
on ice in a cuvette and exposed to an electric pulse. The cuvette was ﬁlled with bacteria
culture medium and bacteria were spread on agar-plates for selection.
Mammalian cells were transfected with Lipofectamine 2000 for plasmids and with Interferin
for siRNAs. For the transfection of plasmids, Lipofectamine 2000 and plasmids were equi-
librated in Opti-MEM for 5-10 min in separate tubes. Then, they were mixed in a ratio
1 to 2 up to 1 to 5 DNA to Lipofectamine 2000 and incubated for 20 min. Meanwhile,
cell culture medium on about 70-90% conﬂuent cells was exchanged to Opti-MEM and the
DNA-Lipofectamine 2000-mixture was added for 4 h. Then, transfection medium was ex-
changed with cell culture medium or cell culture medium was added to the transfection
medium. For the transfection of siRNA, 16 h prior to transfection 5000 cells were plated
per well of a 24-well plate. Then 100 휇l Opti-MEM were mixed with 7 휇l 125 nM siRNA
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and 2 휇l Interferin and incubated for 10 min. Meanwhile cell culture medium on cells was
set to 500 휇l cell culture medium per well of a 24-well plate and 100 휇l of the transfection
mixture was added for 48 h to 72 h.
6.2.2.6. Imaging
Immunoﬂuorescence microscopy For immunoﬂuorescence, cells were grown on glass cover-
slides to about 80% conﬂuency. Depending on the experiment cells were either transfected
with DNA or siRNA (see 6.2.2.5) or were directly ﬁxed with 3% w/v paraformaldehyde in
PBS for 30 minutes, washed with PBS, blocked and permeabilized for 30 minutes in PBS
containing 0.5% BSA and 0.1% saponin (blocking buﬀer, BB). Cells were incubated with
primary antibodies for 1 h in BB, washed three times with BB, incubated with secondary
antibody in BB, washed three times in PBS and counterstained with Bodipy 493/503 or
LD540 [186] in PBS, followed by three washes in PBS. After rinsing in water, coverslips
were mounted in Mowiol 4-88 containing 2.5% 1,4-diazabicyclo[2.2.2]octane. When anti-
body incubations were not required, cells were ﬁxed without permeabilization and then
stained with DAPI and BODIPY 493/503. Images were acquired with laserpoint scanning
confocal microscopes, either a Zeiss LSM 510 or a Zeiss Meta microscope, equipped with a
100x NA 1.3 oil objectives and laser excitation at 351/364 nm, 488 nm, 543 nm and 633 nm.
Quantiﬁcation of ﬂuorescent images was done with Image J particle analysis of the lipid
droplet detecting channel. For A431 cells threshold was set to 723-maximum, for HuH7
cells to 100-maximum, circularity 0-1 and particle detection only at a size between 0,02 and
20 휇m2.
Electron microscopy Lipid droplets were isolated as described in 6.2.2.7 and bound to
electron microscopy grids. These four hundred mesh grids were coated with formvar and/or
with a thin carbon coat. The carbon coat was charged with a glow-discharger and exposed
to a droplet of lipid droplet containing solution for 2 min. The droplet was exchanged to a
droplet of 3% molybdate pH 7.0 or 4% uranylacetate pH 6.0. The droplet was either dried
on the grid or removed by washing 2 times with 20 mM Hepes/NaOH, pH 7.4.
6.2.2.7. Lipid droplet isolation and density gradients
Cells were grown in 10 cm dishes in normal medium or medium supplemented with 50-100 휇M
oleate for 16 h, washed and scraped in ice-cold disruption buﬀer (20 mM Hepes/NaOH, pH
7.4, 0.25 M sucrose) followed by homogenization in a cooled EMBL cell-cracker (HGM,
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Heidelberg, GER) with ﬁve strokes using a maximum clearance of 18 휇m. The lysate was
centrifuged at 1000 g for 10 min, and the post-nuclear supernatant (PNS) was adjusted to
1.1 M sucrose. Four ml of the PNS were loaded to the bottom of a 13 ml centrifuge tube
and overlaid with ice-cold disruption buﬀer. The gradients were centrifuged in a swing-out
rotor at 100.000 g at 4°C for 2.5 h up to over-night. Fractions were taken from the top as
follows: top 2 ml - LD fraction, next 3.5 ml - intermediate fraction, next 4 ml including the
phase boundary between 0.25 and 1.1 M sucrose - ﬂoating membranes, last 3.5 ml - bottom
fraction. For lipid mass spectrometry, cells were grown in medium supplemented with 10%
FCS and 20% horse serum and a layer of 0.5 M sucrose with 100 mM NaHCO3 pH 11.5 was
included between PNS and ice-cold disruption buﬀer. For electron microscopy, the top two
to three ml were exchanged to 20 mM Hepes/NaOH, pH 7.4 without sucrose. For localiza-
tion of DGAT2 and ACSL1 in COS7 cells a stepwise sucrose gradient ranging from 15 to
70% sucrose was used. Sample was loaded on a 70% sucrose layer and further sucrose layers
were added containing 60%, 58%, 55%, 52%, 50%, 48%, 45%, 40%, 35%, 30%, 25% and
15% sucrose. After centrifugation 500 휇l fractions were taken, proteins were separated by
SDS-PAGE and analyzed by western blot using anti-DGAT2 and anti-ACSL1-HA as well as
organelle speciﬁc antibodies.
6.2.2.8. ApolipoproteinB, lipid and hepatitis C virus secretion
HuH7 cells were plated in 24-well plates (5000 cells per well) 16 h prior transfection. Cells
were transfected with siRNAs (control siRNA scrambled#5 or #6 and siRNA against
LPCAT1 siRNA1#1 and siRNA1#3). Transfection was performed in 100 휇l Opti-MEM
and 500 휇l serum-free supplemented RPMI medium.
In case of apoB determination by apoB ELISA, siRNAs were removed after 24 h and cells
were grown further for 48 h in 200 휇l serum-free RPMI. Supernatants were collected 72 h
after transfection and they were subjected to apoB ELISA. The corresponding cells were
scraped into PBS and total protein content was measured with BIORAD protein assay. The
amount of apoB released was quantiﬁed by ELISA, normalized to the total protein content
and compared to control.
In case of apoB determination by western blot, supernatants were collected 72 h after trans-
fection and mixed with 5xLa¨mmli buﬀer and corresponding cells were scraped in 50 휇l
La¨mmli buﬀer. Supernatant (40 휇l) and cell lysates (15 휇l) were subjected to SDS-PAGE
and western blot and analyzed for apoB and LPCAT1 and GAPDH, respectively. The
amounts of apoB and LPCAT1 were normalized to GAPDH and compared to control.
In case of radioactive quantiﬁcation of lipid release, 1 휇Ci [3H]oleate was added to the
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medium to each well of a 24-well plate for 24 h. Then, remaining radioactivity and siRNAs
were removed and cells were grown further in 200 휇l serum-free supplemented RPMI medium
for 48 h. Supernatants were collected 72 h after transfection and lipids were extracted (see
6.2.3.3). The extracted lipids were separated by thin layer chromatography (see 6.2.3.3) or
quantiﬁed by scintillation counting.
For density determination of apolipoproteinB containing lipoprotein particles, they were
separated by diﬀerential centrifugation. Five hundred 휇l serum-free supernatant collected
from HuH7 cells after three days was laid on top of 500 휇l density medium with a density
of 1,006 kg/l (0.19 M NaCl, 0.27 mM EDTA, 1 mM NaOH) and centrifuged for 100 min
at 60.000 g at 18°C. The top 450 휇l were removed, the rest mixed and 500 휇l were mixed
with 500 휇l of density medium with a density of 1,120 kg/l (0.19 M NaCl, 0.27 mM EDTA,
1 mM NaOH, 0.85 M NaBr). Centrifugation was repeated and the top 450 휇l were collected.
The rest was mixed and 500 휇l were mixed with 500 휇l of density medium with a density of
1,340 kg/l (0.19 M NaCl, 0.27 mM EDTA, 1 mM NaOH, 5.25 M NaBr). Centrifugation and
collection was repeated and the rest was mixed and 450 휇l were collected. Proteins from
all collected samples were precipitated with chloroform/methanol and dissolved in La¨mmli
buﬀer. Proteins were separated by SDS-polyacrylamide gel electrophoresis.
For the measurement of hepatitis C virus (HCV) replication and release, HuH7.5 cells,
HuH7.5 ﬁreﬂy cells and the recombinant HCV Jc2Ra were used. First, 3 x 104 Huh7.5
ﬁreﬂy cells were seeded and 24 h later transfected with interferin and the indicated siRNAs
(1.5 nM) or mock transfected. About 24 h post transfection the mixtures were removed
and fresh DMEM was added to the cells. About 40 h after transfection, cells were infected
(original infection) with the Jc1 derived Jc2Ra reporter HCV at the indicated MOI. About
24 h post infection the medium was replaced by 500 휇l of fresh DMEM and about 72 h
post infection the supernatants were collected and 300 휇l were used to infect Huh7.5 cells
(reinfection), seeded the day before in a 24-well plate (2 x 104 cells). The originally infected
Huh7.5 cells were then lysed and assayed for Renilla Luciferase and Fireﬂy Luciferase counts,
to calculate the levels of HCV replication. The data were then analyzed to calculate the
eﬀect of the siRNAs on viral replication by comparing the ratio between the average repli-
cation in the two controls and after treatment with the siRNA of interest. After 72 h post
reinfection, cells were lysed and assayed for Renilla Luciferase counts, to calculate the levels
of HCV assembly/release. The analysis of HCV replication and secretion was performed by
Gualtiero Alvisi.
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6.2.3. Biochemical methods
6.2.3.1. SDS-polyacrylamide gel electrophoresis, Coomassie staining and western
blot
All samples for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) were prepared in La¨mmli
buﬀer (1x: 62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.002% Bromophenol blue, 10% (w/v)
glycerol, 1% 훽-mercaptoethanol). The Bio-Rad (Munich, Germany) Mini-protean system
and the following solutions were used: 1x running Buﬀer (25 mM Tris, 192 mM glycine, 0.1%
SDS), 4x separating gel buﬀer (1.5 M Tris-HCl pH 8.8, 0.4% (w/v) SDS), 4x stacking gel
buﬀer (0.5 M Tris-HCl pH 6.8, 0.4% SDS), 30% acrylamide stock (30% (w/v) acrylamide,
0.8% (w/v) bisacrylamide), TEMED and 10% ammonium persulfate stock. The gels are
either stained with Coomassie blue solution (0.25% (w/v) Coomassie brilliant blue R250,
40% methanol, 10% acetic acid, 50% water) and destained with destaining solution (40%
methanol, 10% acetic acid, 50% water) and dried in a gel dryer or the gels were used for
western blot. The proteins in the gels were blotted onto a nitrocellulose membrane from
Whatman (Dassel, Germany) by semidry transfer using the semidry blotting buﬀer (40%
1x running buﬀer, 20% methanol, 40% water) or by wet blot transfer using the wet blotting
buﬀer (10% running buﬀer, 20% methanol, 70% water). Successful transfer was validated by
PonceauS staining of the membrane followed by blocking with blocking solution (PBSMT:
PBS containing 4% (w/v) milk powder and 0.2% Tween-20). The membrane was incubated
with the primary antibody in PBSMT for 1 h up to over-night. Unbound antibody was
removed by three washes with PBSMT followed by incubation with the secondary anti-
body for 1 h. Unbound antibody was removed by three washes with PBSMT, two washes
with PBST and two washes with PBS. Protein detection was performed with ECL western
blot detection reagent from GE Healthcare and Biomax Light ﬁlms from Kodak or ECL
Hyperﬁlms from GE Healthcare.
6.2.3.2. Protein topology
Selective membrane permeabilisation For analysis of protein membrane topology by
immunoﬂuorescence, cells were plated on glass coverslips, transfected with either the N- or
C-terminally tagged protein of interest, ﬁxed and permeabilized with 0.1% saponin (per-
meabilizes all cellular membranes) or with 0.001% digitonin (permeabilizes only the plasma
membrane) and stained with antibodies against HA-tag, C-terminus of LPCAT1 or LPCAT2
and the luminal ER protein PDI. For further detail on staining procedure see 6.2.2.6.
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Digestion protection A 10 cm dish of COS7 or A431 cells was transfected with the N-
and C-terminally tagged protein of interest. The cells were scraped into ice-cold PBS and
squeezed through a 0.7x40 mm needle. Cell lysates were centrifuged at 600 g for 5 min
and supernatant was divided into three tubes and centrifuged at 100.000 g for 30 min. The
supernatant was removed and replaced by 100 휇l PBS, 100 휇l PBS with 1% TritonX-100 and
100 휇g Proteinase K or 100 휇l PBS with 100 휇g Proteinase K for 1 h at room temperature.
The reaction was stopped by the addition of 1 mM PMSF and 25 휇l 5xLa¨mmli buﬀer.
Proteins were separated by SDS-PAGE and analyzed by western blot for the N- and C-
terminal tags and the luminal ER protein PDI.
Membrane association A 10 cm dish of COS7 cells was transfected with a vector for
expression of the DGAT2 wildtype protein. Membranes were collected as described above in
6.2.3.2 except that supernatant was divided into six instead of three tubes. Membranes were
then incubated for 30 min with 100 휇l PBS, 100 휇l PBS with 1 M NaCl, 100 휇l PBS with
6 M urea, 100 휇l PBS with 0.1 M NaCO3, 100 휇l PBS with 1% TritonX-100 or 100 휇l PBS
with 1% dodecylmaltoside. Then, samples were centrifuged again at 100.000 g for 30 min
and supernatant and pellet were mixed with La¨mmli buﬀer. Proteins were separated by
SDS-PAGE and analyzed by western blot for the abundance of DGAT2 and the single-span
membrane protein calnexin.
6.2.3.3. Radioactive labeling, extraction and identiﬁcation of cellular lipids
Metabolic labeling with radioactive precursors Cells were either labeled with [3H]oleate
for 6 h up to 24 h by adding 1 휇Ci per well of a 24-well plate or with [14C]acetate for 6 h
by adding 0.5 휇Ci per well of a 24-well plate to the cell culture medium. The lipids are
extracted from cells, separated by TLC or quantiﬁed as described in the following para-
graphs. For labeling of proteins with [35S]methionine cells were transfected 20 h prior to
labeling and kept in Dulbeccos modiﬁed Eagles medium without pyridoxine hydrochloride,
L-glutamine, sodium pyruvate, L-methionine and L-cysteine for 1 h before the addition of
0.2 mCi [35S]methionine and 10% FCS for 4 h. Proteins were isolated from cells by im-
munoprecipitation as described in section 6.2.3.6.
Lipid extraction For extraction of cellular lipids directly from a 24-well cell culture dish,
cells were washed 1x with ice-cold PBS with 1% BSA and 2x with ice-cold PBS. Then,
30-50 휇l methanol/chloroform (5:1) was added to the cells and the liquid was transferred
directly to a thin layer chromatography plate. For lipid extraction from cell supernatants
80
6.2. Methods
or activity assays, liquids were mixed with 750 휇l methanol/chloroform (3:1) and 400 휇l
water. The mixture was centrifuged at 13.000 rpm for 5 min and the lower lipid containing
chloroform phase was transferred to a new tube. Chloroform was removed in vacuo and the
lipid pellet was dissolved in 30 휇l methanol/chloroform (1:2). Lipids were separated by thin
layer chromatography.
Separation of lipids by thin layer chromatography Thin layer chromatography plates
(TLC) plates were loaded with lipid containing solutions with a capillary. Plates were run
in solvent 1 (35 ml triethylamine, 50 ml ethanol, 10 ml water, 35 ml chloroform) for 1 h
and in solvent 2 (100 ml iso-hexane and 20 ml ethylacetate or 95 ml iso-hexane, 23.8 ml
diethylether and 1.2 ml acetate) for 30 min. Dried plates were either sprayed with sulfuric
acid to stain the lipids or in case of radioactive labeled lipids exposed on phosphoimager
plates (for [14C]) or dipped into Lumasafe scintillation liquid and exposed to Hyperﬁlm MP
at -80°C (for [3H]).
Quantiﬁcation of lipids Lipids were either quantiﬁed from autoradiography ﬁlms or phos-
phoimager plates with the software IMAGEGAUGE and compared to controls or standards
or were quantiﬁed directly from the TLC plate on a Biospace Beta-Imager 2000 or in the scin-
tillation counter. For scintillation counting, lipidspots were scraped from the TLC plate and
homogenized 30 min by ultrasoniﬁcation in 1 ml chloroform/ethanol/water (49.5:49.5:1).
Then, they were centrifuged for 10 min at 13.000 rpm and supernatant was transferred
into scintillation tubes. The liquid was evaporated and the pellet was dissolved in 2 ml
ethanol. Then, 15 ml Lumasafe scintillation liquid was added and measured in the scintil-
lation counter with the appropriate program. Lipids in solution were measured directly by
mixing with Lumasafe scintillation liquid and measuring in the scintillation counter.
6.2.3.4. Protein and lipid mass spectrometry
For the analysis of the lipid droplet proteome, A431 cells (8 x 10 cm dishes) were grown
as described in section 6.2.2.2 and supplemented with 100 휇M oleate for the ﬁnal 16 h.
Cells were lysed and LDs were puriﬁed exactly as described in section 6.2.2.7 with the
exception of the addition of Roche Complete protease inhibitor tablets to all buﬀers. Proteins
from pooled LD fractions were precipitated using chloroform/methanol, subjected to one-
dimensional SDS-PAGE (10% acrylamide gel) and visualized by Coomassie brilliant blue
(CBB) staining. The lane was cut into 34 bands that were separately digested with trypsin
[187] and recovered peptides were analyzed by LC-MS/MS on LTQ linear ion trap mass
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spectrometer. This experiment was performed by Christoph Thiele and Anna Shevchenko.
For the analysis of the proteins interacting with the N-terminus of DGAT2, eluates from
the streptavidin-sepharose-SBP-tag-column (see 6.2.3.6) were separated by SDS-PAGE and
stained with Coomassie. Visible bands were cut out, staining and salts were removed and
proteins were digested with trypsin. Protein fragments were crystalized and analyzed by
MALDI-TOF mass spectrometry. This analysis was performed by Cornelia Czupalla.
For lipid mass spectrometry, cell lysates, ﬂoating membranes or LDs (in 200 휇l 155 mM
NH4HCO3) were mixed with 20 휇l internal lipid standard mixture providing a spike of
57 pmol PE 17:0/17:0, 47 pmol PC 18:3/18:3, 47 pmol SM 17:0, 37 pmol DAG 17:0/17:0,
37 pmol TAG 17:1/17:1/17:1 and 57 pmol CE 17:0. Samples were extracted with 990 휇l
chloroform/methanol (15:1) for 120 min at 4°C [188]. The apolar organic phase was isolated
and evaporated. Lipid extracts were dissolved in 200 휇l of 7.5 mM ammonium acetate
in chloroform/methanol/2-propanol (1:2:4) and subjected to quantitative lipid analysis in
positive ion mode on a QSTAR Pulsar-i instrument (MDS Analytical Technologies) or a LTQ
Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc) equipped with a TriVersa NanoMate
nanoﬂow ion source (Advion Biosciences, Inc., Ithaca, NJ) [188–191]. This analysis was
performed by Christer Ejsing.
6.2.3.5. Enzyme activity assays
LPCAT and LPAAT activity assay Whole cell lysates (15 휇l or 50 휇l for HuH7 cell
lysates upon LPCAT1 knock-down) or LD fractions from sucrose gradient centrifugation
(200 휇l) were mixed with 100 휇l of assay buﬀer (200 mM Tris/HCl pH 7.5, 10 mM MgCl2,
2 mg/ml fatty acid free BSA, 10 휇M oleoyl-CoA, 10 휇M palmitoyl-CoA, 1 휇Ci/ml each of
[3H]oleoyl-CoA, [3H]palmitoyl-CoA and [3H]myristoyl-CoA). For the LPAAT assay, 100 휇M
sn-1-palmitoyl-sn2-lyso-PA, for the LPCAT assay 100 휇M sn-1-palmitoyl-sn2-lyso-PC were
added and incubated for 30 min at 30°C or 15 min at 37°C for HuH7 cell lysates upon
LPCAT1 knock-down. Reactions were stopped by lipid extraction. Lipids were separated
by TLC and plates were either analyzed on a Biospace Beta-Imager 2000 or were sprayed
with scintillant and exposed to a X-ray ﬁlm at -80°C.
Diacylglycerol cholinephosphotransferase assay Whole A431 cell lysates (50 휇l ) or a
mixture of bottom (50 휇l) and membrane fraction (50 휇l) or LD fractions from sucrose
gradient centrifugation (200 휇l) were mixed with 100 휇l of assay buﬀer (50 mM Tris-HCl pH
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8.0, 10 mM MgCl2, 100 휇M DODG, 0.5 휇Ci [14C]CDP-choline, 200 휇M CDP-choline) and
incubated for 30 min at 37°C. The same procedure as described for LPCAT assay followed.
DGAT2 activity assay Aliquots of the LD fraction (200 휇l) or bottom fraction (120 휇l)
were mixed with 100 or 180 휇l, respectively, of assay buﬀer (200 mM Tris, pH 7.4, 10 mM
MgCl2, 2 mg/ml delipidated BSA, 20 휇M oleoyl-CoA, 20 휇M palmitoyl-CoA, 0 or 200 휇M
dioleoylglycerol, 0.35 휇Ci each of [9,10-3H]-oleoyl-CoA, [9,10-3H]-palmitoyl-CoA, and [9,10-
3H]-myristoyl-CoA) and incubated at 30°C for 1 h. A control sample replacing the LD
fraction with homogenization buﬀer was carried along. Lipids were extracted, separated by
TLC in iso-hexane/diethylether/acetic acid 80:20:1, and visualized by autoradiography.
ACSL1 activity assay Proteins were coimmunoprecipitated as described in 6.2.3.6. The
beads with the precipitate (100 휇l) were incubated with 100 휇l assay buﬀer (200 mM Tris-
HCl pH 7.4, 20 mM MgCl2, 0.01 M DTT, 20 mM ATP, 0.6 mM CoA, 0.05 mM oleate,
0.05 mM palmitate, 1 휇Ci [3H]oleate, 1 휇Ci [3H]palmitate) for 1.5 h at 37°C. The reac-
tion was stopped by the addition of 400 휇l isopropanol/iso-hexane/1M HCl (79:19:2). The
mixture was centrifuged for 3 min at 13.000 rpm and the supernatant was transferred to
a new tube. Beads were pelleted and supernatants were collected. FFAs were extracted
from supernatants by the addition of 140 휇l water and 250 휇l iso-hexane. The mixture
was centrifuged for 3 min at 13.000 rpm, the upper hexane layer was removed and the rest
was mixed with 300 휇l iso-hexane. The upper hexane layer was removed and the procedure
was repeated two to three times. Then, 350 휇l of the lower layer were transferred to a
scintillation tube and mixed with the same amount of methanol and with 15 ml Lumasafe
scintillation liquid. Then, the activity of the remaining product [3H]acyl-CoA in the lower
layer was measured in the scintillation counter.
6.2.3.6. Identiﬁcation of protein-protein interaction
Protein expression and puriﬁcation The empty pET24D vector, the pET24D-EGFP-
tags vector and the pET24D-N(200)hDGAT2-TEV-3HA-P-SBP vector were transfected into
the expression bacteria strain ER2566. The transfected strains were grown at 18°C from
OD 0.1 till OD 0.5, then protein expression was induced with 0.1 mM isopropyl-beta-D-
thiogalactopyranoside at 18°C over-night. Bacteria were collected by centrifugation, the
pellet was homogenized in 10 ml lysis buﬀer (40 mM HEPES pH 7.2, 150 mM NaCl, 2 mM
EDTA, 50 mM NaF, 0.2 mM NaOrthovanadate, Roche proteinase inhibitor) and frozen at
-20°C. After thawing, bacteria were lysed with an emulsiﬂex and lysates were centrifuged for
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1 h at 23.000 g to remove membrane debris. An aliquot of each bacteria strain lysate was
tested by SDS-PAGE and western blot for the expression of the appropriate protein. Mean-
while, streptavidin-sepharose was equilibrated at 4°C, ethanol was removed and the column
was washed with bacterial lysis buﬀer. Then, lysates were incubated with streptavidin-
sepharose for 4 h at 4°C to speciﬁcally bind the desired proteins via their SBP-tag. The
lysates were removed and the column was washed 2x with three volumes bacteria lysis buﬀer
and equilibrated with 2x three volumes recruitment buﬀer (25 mM HEPES pH 7.2, 125 mM
potassium acetate, 2.5 mM magnesium acetate, 1 mM DTT, 5 mM potassiumdihydrogen-
phosphate, 5 mM glycerol-3-phosphate, Roche proteinase inhibitor).
Liver cytosol preparation Pig (Sus scrofa) liver was cut into small pieces, which were fur-
ther homogenized in recruitment buﬀer by douncing. Then, the homogenate was centrifuged
for 10 min at 10.000 g and the supernatant was centrifuged again for 1 h at 100.000 g. The
supernatant was collected as cytosol and the pellet was resuspended in recruitment buﬀer
and collected as membranes. Protein amount was measured and aliquots were frozen at
-80°C.
Streptavidin-sepharose-SBP-tag-column Liver cytosol, membrane and a mixture of both
(membranes + cytosol) were diluted with recruitment buﬀer. The membrane and membrane
+ cytosol samples contained additionally 1% dodecylmaltosid. Samples were incubated
with empty streptavidin-sepharose beads. The samples were then added to the SBP-tagged
protein loaded streptavidin-sepharose columns (see 6.2.3.6) and incubated over-night. The
supernatant was removed and the column was washed with recruitment buﬀer and buﬀers
with increasing salt concentration (40 mM HEPES pH 7.2 with 10 mM, 30 mM, 50 mM,
100 mM, 150 mM, 200 mM, 300 mM NaCl). The SBP-tagged proteins were eluted from
the column together with its binding partners by the addition of elution buﬀer (lysis buﬀer
with 2.5 mM desthiobiotin). Eluates were separated by SDS-PAGE and gels were stained
with Coomassie. Speciﬁc bands were cut out and analyzed by protein mass spectrometry
(see 6.2.3.4).
Immunoprecipitation Protein A-coupled sepharose beads (60 휇l 50% slurry per tube)
were washed with PBS and blocked with PBS-1% BSA, washed with PBS and IP lysis
buﬀer (20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM EDTA, 1% TritonX-100, 0.5% NaDes-
oxycholate, 0.2 mM NaOrthovanadate, 75 mM NaF, Roche proteinase inhibitor). Antibodies
(DGAT2 1:2, HA (F7) 1:6) were added with IP lysis buﬀer for 3 h and washed with PBS-1%
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BSA, PBS and IP lysis buﬀer. Either wildtype or transfected COS7 cells were grown in
6-well plates or 10 cm dishes and were scraped into IP lysis buﬀer. Lysates were rotated
for 10 min at 4°C and centrifuged at 13.000 rpm. The supernatant was incubated with
blocked protein A-coupled sepharose beads for 3 h. Then, the supernatant was incubated
with the antibody protein A-coupled sepharose beads over-night. The supernatant was re-
moved and beads were washed 3x with 400 휇l light wash buﬀer (20 mM HEPES pH 7.4,
0.5% CHAPS, 0.2 mM NaOrthovanadate, 75 mM NaF, Roche proteinase inhibitor) and 1x
with 400 휇l hard wash buﬀer (150 mM NaCl, 2 mM EDTA, 100 mM Tris-HCl pH 8.3,
0.1% SDS, 0.5% Nonidet P40, 0.5% NaDesoxycholate, 0.2 mM NaOrthovandate, 75 mM
NaF, Roche proteinase inhibitor). Beads were mixed with La¨mmli buﬀer, proteins were
separated by SDS-PAGE and analyzed by western blot. All washing and incubation steps
were performed on a rotating wheel at 4°C and beads were pelleted by centrifugation. In
case of the IP followed by the ACSL1 assay (6.2.3.5), beads were sedimented by gravitation
and modiﬁed IP lysis buﬀer (20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM EDTA, 0.8%
digitonin, 0.2 mM NaOrthovanadate, 75 mM NaF, Roche proteinase inhibitor) and wash
buﬀer (20 mM HEPES pH 7.4, 0.2% digitonin , Roche proteinase inhibitor) were used.
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A. Supplementary ﬁgures
Figure A.1.: DGAT2 localization under oleate-fed conditions
The immunoﬂuorescence image of DGAT2 and LDs under oleate-fed conditions show in ﬁgure 4.1 is split into single
channels: ﬁrst image, LDs; second image, DGAT2; third image, merged. Scalebar = 10 휇m
Figure A.2.: Coomassie gel for LD protein mass spectrometric analysis
Proteins were isolated from puriﬁed lipid droplets of oleate-fed A431 cells and were subjected to SDS-PAGE followed
by Coomassie brilliant blue staining. The lane was cut into 34 slices, each of which was separately digested with
trypsin and analyzed by LC-MS/MS. This ﬁgure is provided by Christoph Thiele.
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Figure A.3.: Characterization of antibodies against LPCAT1 and LPCAT2
Left panel: HuH7 cells were transfected with vectors for LPCAT1 (lanes 1, 3, 5) or LPCAT2 (lanes 2, 4, 6), both
bearing an N-terminal 3HA-tag. Total cell lysates were subjected to SDS-PAGE followed by western blotting. Three
identical blots were probed with anti-LPCAT1 (lanes 1+2), anti-LPCAT2 (lanes 3+4), and anti-HA (lanes 5+6).
Right panel: Total lysates of non-transfected A431 cells were subjected to SDS-PAGE/western blotting and probed
with anti-LPCAT1 and anti-LPCAT2.
Figure A.4.: Purity of LD fractions used for lipid mass spectrometry
The ﬁgure shows ESI Time-of-Flight mass spectra of isolated LDs of A431 cells (upper panel), ﬂoating membranes
of A431 cells (middle panel) or whole cell lysates of A431 cells (lower panel). Note that lysates contain a mixture
of phospholipids and TAG, while ﬂoating membranes contain mostly phospholipids, and LDs mostly TAG. This
diagram and lipid mass spectrometry is provided by Christer Ejsing.
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Figure A.5.: Silencing of LPCAT1 and LPCAT2 in A431 cells does not inﬂuence TAG synthesis
A431 cells were grown and transfected with siRNA as described in ﬁgure 4.12. [3H]oleate was added for further 24 h
to the cells either directly (day 1) or 24 h (day 2) after transfection. Lipids were extracted, separated by TLC and
visualized by autoradiography. Only the region of newly synthesized [3H]TAG is shown.
Figure A.6.: Silencing of LPCAT1 and LPCAT2 in A431 cells does not inﬂuence the amount of stored
TAG
A431 cells were transfected as described in ﬁgure 4.12. After 48 h, total lipid extracts were analyzed by mass
spectrometry. Each sample was measured in duplicate, and species abundances were normalized to the corresponding
internal standard. The molar contents of each species of the same class were summed up and normalized to the total
content of all detectable lipids. This diagram and lipid mass spectrometry is provided by Christer Ejsing.
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Figure A.7.: Inhibition of PC de novo synthesis channels fatty acids towards TAG synthesis
A431 cells were grown in DMEM medium with 10% FCS or in DMEM without choline with 10% FCS. [3H]oleate
was added for 24 h to the cells. Lipids were extracted, separated by TLC and visualized by autoradiography. The
panel shows the changes in the ratio of PC and TAG labeled by incorporation of [3H]oleate upon choline deﬁciency.
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A. Supplementary ﬁgures
Figure A.9.: Silencing of LPCAT1 and LPCAT2 in choline-depleted A431 cells does not inﬂuence
TAG synthesis
Same experiment as in supplementary ﬁgure A.5, but cells were grown in choline-free medium after the siRNA
transfection
Figure A.10.: Silencing of LPCAT1 and LPCAT2 in choline-depleted A431 cells does not inﬂuence
the amount of stored TAG
Same experiment as in supplementary ﬁgure A.6, but cells were grown in choline-free medium after the siRNA
transfection. Additionally, this panel contains data of control cells grown in normal medium to demonstrate the
inﬂuence of choline depletion. This diagram and lipid mass spectrometry is provided by Christer Ejsing.
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A. Supplementary ﬁgures
Figure A.12.: ApoB secreted by HuH7 cells is associated with lipoprotein particles
HuH7 cells were grown in serum-free supplemented RPMI medium for three days. Supernatant was collected and
sequentially centrifugated with diﬀerent density buﬀers. Density fractions and cell lysates as indicated were collected,
proteins precipitated and analyzed by SDS-PAGE and western blot for apoB. Note that 8-times more cell lysate than
density fractions was loaded.
Figure A.13.: Secreted radioactively labeled lipids from HuH7 cells
HuH7 cells were grown in serum-free supplemented RPMI medium and transfected with scrambled siRNA (Control)
or siRNA targeting LPCAT1 were grown for 24 h in the presence of [3H]oleate. The siRNAs and radioactivity were
removed and cells were grown further for 48 h in serum-free supplemented RPMI medium. Lipids were extracted
from supernatant and cells and separated by TLC.
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Figure A.14.: Hydrophobicity plots of human LPCAT1 and LPCAT2
Hydrophobicity proﬁles of human LPCAT1 and LPCAT2 were calculated using the Kyte-Doolittle algorithm with a
window of 17 amino acids. Note the single long hydrophobic stretch close to the N-terminus of the proteins. This
ﬁgure is provided by Christoph Thiele.
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Figure A.15.: Topology of LPCAT1
A431 cells were transfected with vectors coding for LPCAT1 with either N-terminal 3HA-tag (HA-LPCAT) or C-
terminal 3HA-tag (LPCAT-HA) and were cultivated for 16 hours in the presence of 100 휇M oleate. Cells were ﬁxed
and processed for immunoﬂuorescence microscopy using either saponin (permeabilizes all membranes) or digitonin
(permeabilizes plasma membrane, but not the ER membrane) for permeabilization. Cells were stained with BODIPY
493/503 to stain LDs (lipid droplets, green in the merged picture), anti-HA to detect transfected LPCAT proteins
(LPCAT1, red) and anti-PDI (PDI, blue) as a lumenal ER marker.
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Figure A.16.: Topology of LPCAT2
As described in supplementary ﬁgure A.15, but A431 cells were transfected with vectors coding for LPCAT2. Lipid
droplets are green, anti-HA to detect transfected LPCAT2 proteins is red and PDI as a lumenal ER marker is blue
in the merged pictures.
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Figure A.17.: Coomassie gels for identiﬁcation of DGAT2 interaction partner
The coomassie gels show the proteins accumulated in the eluates of the columns used to isolate speciﬁc interaction
partner of DGAT2. In lane 1 (control (beads)) the proteins in the eluate of the column loaded with empty vector
expressing bacteria lysates, in lane 2 (N-terminus of DGAT2) the eluate of the column loaded with the bacterial
expressed construct described in ﬁgure 4.30a and in lane 3 (control (tag)) the eluate of the column loaded with a
EGFP control construct (EGFP cloned in front of the tag described in ﬁgure 4.30) are shown. The left gel represents
the proteins bound from pig liver cytosol, the middle gel represents proteins bound from pig liver membranes +
cytosol and the right gel represents proteins bound from pig liver membranes. Bands labeled with letters (A-D, a)
or numbers (1-7) only appeared in lane 2 and were cut out and analyzed by mass spectrometry (see table B.4).
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Figure A.18.: Cellular localization of DGAT2 and ACSL1 under delipidated conditions
COS7 cells were transfected with empty vector (control), human C-terminal HA-tagged ACSL1 (ACSL1-HA), wild-
type human DGAT2 (DGAT2) or wildtype human DGAT2 and human C-terminal HA-tagged ACSL1 (ACSL1-HA
+ DGAT2) for 24 h. Cells were grown in DMEM medium supplemented with delipidated FCS. Cells were analyzed
by immunoﬂuorescence for lipid droplets (green), ACSL1 (blue) and DGAT2 (red). Scalebar = 10 휇m.
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Figure A.19.: Cellular localization of DGAT2 and ACSL1 under oleate conditions
COS7 cells were transfected with empty vector (control), human C-terminal HA-tagged ACSL1 (ACSL1-HA), wild-
type human DGAT2 (DGAT2) or wildtype human DGAT2 and human C-terminal HA-tagged ACSL1 (ACSL1-HA
+ DGAT2) for 24 h. Cells were grown in DMEM medium supplemented with FCS and 100 휇M oleate. Cells were
analyzed by immunoﬂuorescence for lipid droplets (green), ACSL1 (blue) and DGAT2 (red). Scalebar = 10 휇m.
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Figure A.20.: Interaction with ACSL1 does not increase DGAT2 activity in COS7 cells
COS7 cells were transfected with empty vector (control), human C-terminal HA-tagged ACSL1 (ACSL1), wildtype
human DGAT2 (DGAT2) or transfected with wildtype human DGAT2 and human C-terminal HA-tagged ACSL1
(ACSL1/DGAT2) for 24 h. Cells were grown further in DMEM/FCS medium supplemented with [3H]labeled oleate
for 6 h or 24 h either with (+) or without (-) additional 100 휇M non-radioactively labeled oleate. Lipids were
extracted, separated by TLC and detected by autoradiography. The TAG signal obtained from control cells was
normalized to 1.
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Figure A.21.: Interaction of ACSL1 and DGAT2 does not change fatty acid ﬂux in COS7 cells
COS7 cells were transfected with empty vector (vector), human C-terminal HA-tagged ACSL1 (ACSL1), wild-
type human DGAT2 (DGAT2) or with wildtype human DGAT2 and human C-terminal HA-tagged ACSL1
(ACSL1/DGAT2) for 24 h. Cells were further grown in DMEM/FCS medium supplemented with [14C]labeled
acetate for 6 h. Lipids were extracted, separated by TLC and detected by autoradiography.
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Figure A.22.: Interaction with ACSL1 does not inﬂuence stability of DGAT2 in COS7 cells
COS7 cells were transfected with wildtype human DGAT2 (DGAT2) or with wildtype human DGAT2 and human
C-terminal HA-tagged ACSL1 (ACSL1 + DGAT2) for 24 h. Proteins were labeled with [35S]methionine and labeled
DGAT2 protein was immunoprecipitated with the DGAT2 antibody after diﬀerent chase times. Proteins in the
immunoprecipitate were separated by SDS-PAGE and analyzed by autoradiography. The acquired speciﬁc DGAT2
bands were quantiﬁed with IMAGEGAUGE and compared to the maximum signal obtained after [35S] labeling.
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B. Supplementary tables
Table B.1.: Mass spectrometric analysis of LD proteins from A431 cells
The numbers indicate protein bands of the coomassie gel shown in supplementary ﬁgure A.2, which were analyzed
by mass spectrometry. The resulting list of more than 700 identiﬁed proteins was sorted according to the abundance
index (A-index, [192]) with a cut-oﬀ of 2, which provided 40 abundant proteins. Out of this list, we further removed
20 typical protein contaminants, commonly encountered in biochemical puriﬁcations, such as histones, ribosomal
proteins, cytoskeletal proteins, heat shock proteins and metabolic enzymes. Note that no membrane proteins were
removed. The remaining 20 proteins were annotated according to putative functions: perilipin-adipophilin-TIP47
family members (PAT); enzymes or regulators of lipid metabolism (Lip. Met.); proteins related to ubiquitination
and ubiquitin-dependent protein degradation (Ubiq-PD); and membrane traﬃc (Memb. Traf.). The number of
unique peptides matched to the corresponding sequences and achieved sequence coverage are presented in the table;
LPCAT1 and LPCAT2 are in bold. This table is provided by Ana Shevchenko and Christoph Thiele.
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Table B.2.: Quantiﬁcation of LD size changes upon silencing of LPCAT1 and LPCAT2 by siRNA in
A431 cells
Confocal images as described in ﬁgure 4.13 from three diﬀerent experiments were quantiﬁed with Image J and
mean numbers are displayed for the number of LDs, total ﬂuorescent area measured, LD size per image and the
corresponding signiﬁcances of the diﬀerences in LD size calculated by unpaired two-sided t-test analysis relative to
scrambled#5+#6.
Table B.3.: Quantiﬁcation of LD size changes upon silencing of LPCAT1 by siRNA in HuH7 cells
Confocal images as described in ﬁgure 4.16 from three diﬀerent experiments were quantiﬁed with Image J and
mean numbers are displayed for the number of LDs, total ﬂuorescent area measured, LD size per image and the
corresponding signiﬁcances of the diﬀerences in LD size calculated by unpaired two-sided t-test analysis relative to
wt.
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Table B.4.: Potential interaction partner of DGAT2
In the table the proteins identiﬁed by mass spectrometry in the bands cut from the coomassie gels shown in supple-
mentary ﬁgure A.17 are listed. The numbering of the hits corresponds the numbering of the bands in supplementary
ﬁgure A.17. The grey shaded protein was identiﬁed under two diﬀerent conditions. The mass spectrometric analysis
and the table is provided by Cornelia Czupalla.
107

C. Abbreviations
3T3-L1 mouse ﬁbroblast cell line able to diﬀerentiate into adipocytes
A431 human epithelial ﬁbroblast cell line
ACAT1 acylcholesterol acyltransferase 1
ACSL acyl-CoA synthetase ligase
ADRP adipophilin
ATGL adipose triacylglyceride lipase
CE cholesterol ester
CHO-K2 chinese hamster ovary cell line
COS7 african green monkey kidney ﬁbroblast cell line
CPT CDP-choline 1,2-diacylglycerol cholinephosphotransferase
DAG/DG diacylglycerol, diacylglycerides
DGAT diacylglycerol acyltransferase
ER endoplasmic reticulum
FA fatty acid
FFA free fatty acid
FCS fetal calf serum
GAPDH glycerol-3-phosphate dehydrogenase
HA hemagglutinin
HCV hepatitis C virus
HepG2 human hepatocellular carcinoma cell line
HSL hormone sensitive lipase
HuH7 human hepatoma cell line
LD lipid droplet
LPA lyso-phosphatidic acid
LPAAT lyso-phosphatidic acid acyltransferase
LPC lyso-phosphatidylcholine
LPCAT lyso-phosphatidylcholine acyltransferase
LPE lyso-phosphatidylethanolamine
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C. Abbreviations
MAM mitochondria-associated membrane
NSDHL NAD(P)H steroid dehydrogenase-like protein
PA phosphatidic acid
PAT protein domain named after perilipin, adipophilin and tail-interacting protein 47
PC phosphatidylcholine
PDI protein disulﬁde isomerase
PE phosphatidylethanolamine
PLA2 phospholipase A2
PM plasma membrane
PP pyrophosphate
SM sphingomyelin
TAG/TG triacylglycerol, triacylglycerides
TIP47 tail-interacting protein 47
TLC thin layer chromatography
PI phosphatidylinositol
PS phosphatidylserine
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